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Short introduction to the thesis’ research
Research in this thesis focuses on immunity in breast cancer (BC), zooming in on 
2 main aspects, namely: improved understanding of the lack of immune control, 
particularly lack of T cell control; and the discovery and testing of new targets for 
adoptive T cell therapy. These 2 aspects are covered by Parts 1 and 2 of this thesis, 
respectively. 
BC is one of the most frequently occurring cancers worldwide. In the Netherlands 1 
in 8 women develop BC during their lifetime (source: IKN). In fact, BC is a hetero-
geneous disease comprising of several molecular and histological characteristics 
that can be classified into 4 main subtypes according to the expression of estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor re-
ceptor 2 (HER2). This subtype classification has clinical relevance since it affects 
prognosis and available treatment options. In example, the BC subtypes luminal-A 
(i.e., ER+, PR+, HER2-, low proliferation, often measured by the marker Ki67) and 
luminal-B (i.e., ER+, PR+, HER2 or Ki67hi) have good prognosis (overall survival 
(OS): 94% and 90% respectively). These 2 subtypes also have fairly good treatment 
options, including chemotherapy and endocrine therapy given alone or together with 
modern targeted therapies, such as mammalian target of rapamycin (mTOR) inhib-
itors and cyclin dependent kinase (CDK4/6) inhibitors. The her2 subtype (i.e., ER-, 
PR-, HER2+) has an OS of 83%, and is mainly treated with chemotherapy combined 
with HER2-blocking antibodies. Finally, triple negative breast cancer (TNBC) (i.e., 
ER-, PR-, HER-) has the poorest survival (OS: 77%) and unfortunately limited treat-
ment options, such as cytotoxic agents and, for specific subgroups, since recently 
Poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibition 
(ICI)1–3.
It has been recognized for several years that tumor infiltrating lymphocytes (TILs) 
are frequently present in BC (particularly in ER- subtypes) and that their abundance 
correlates with survival and therapy response4–8. Despite variable frequencies of 
TILs, their prognostic value was observed in all BC subtypes9–11. Hence, in the re-
cent years the development of immune therapies for BC received markedly more 
attention. In a general sense, immune therapies include oncolytic viruses, vaccina-
tion, ICI and adoptive T cell therapy. Treatment with oncolytic viruses is considered 
to specifically infect malignant cells and boost anti-tumor immune responses; cancer 
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vaccines make use of predefined antigens either directly administered in form of 
peptide vaccine or loaded onto dendritic cells that are adoptively transferred; ICI rep-
resents treatment with monoclonal antibodies that target so called immune check-
points, which are expressed by T cells and cancer cells, and aims to (re-)activate the 
anti-tumor T cell response; and adoptive T cell therapy makes use of the patients 
own T cells which encode for a T cell receptor with pre-defined tumor reactivity12–15. 
The latter two forms of immune therapy are integral components of this thesis. To 
date, most immune therapy trials have been performed using ICIs in BC, and these 
trials showed higher initial responses in TNBC when compared to other BC sub-
types (see Chapter 2 for an overview). Notably, objective response (OR) rates to 
ICI monotherapy in metastatic TNBC (mTNBC) do not exceed 5-25%16. These OR 
rates do increase when ICI is combined with cytotoxic agents (OR: 30-40% )16 . As 
a result, anti-programmed cell death receptor ligand 1 (anti-PDL1) antibody atezoli-
zumab combined with nab-paclitaxel, has recently been approved by the food and 
drug association (FDA) and European medicines agency (EMA) for PD-L1-positive 
mTNBC. Nevertheless, these OR rates are considered poor in comparison to other 
immunogenic solid tumor types, such as melanoma (OR: 43-72%), colorectal cancer 
(OR: 14-78%17) lung cancer (OR: 19-33%18). Furthermore, it is particularly hard to 
predict ICI-response in BC. For example, in contrast to the above mentioned tumor 
types, mutational burden is not predictive for ICI response in TNBC19–21 and even 
the currently used biomarker, PD-L1 on immune cells, does not accurately predict 
non-responders22.
Rational and scope of Part 1 
Collectively, these clinical observations urge for better understanding of the interplay 
between the immune system and malignant tumor cells in BC which are studied in 
Part 1 of this thesis. To date, there is little data regarding the shortcomings in CD8 
T cell immunity (i.e., what drivers of immune responses are compromised or lack-
ing) and consequences of effective CD8 T cell immunity (i.e., what immune evasive 
mechanisms come into play) in BC. In this regard, it has been recognized that not 
only numbers of TILs, but also their composition, spatial localization and activation 
state matters23–27 , urging for better understanding of spatial immune contexture in 
BC. Part 1 of this thesis focuses on these knowledge gaps, which is most critical 
to explain the variable and low responses to current immune therapies among BC 
subtypes (explained in detail in Chapters 2 and 3), and may contribute to the devel-
opment of better predictive markers and provide a basis for the development of more 




immunity (see Chapter 4).
Study design and methodology: To this end, we utilized several public and pro-
prietary BC cohorts, including node-negative untreated BC comprising all subtypes 
as well as anti-PD1 treated TNBC and studied antigen load, T cell clonality as well 
as gene-sets and pathways associated with T cell evasion. Furthermore, we stud-
ied the spatial immune contexture and potential drivers of different immunopheno-
types using multiplexed immunofluorescent images on TNBC tissues and assessed 
its prognostic and predictive value. Finally, we evaluated immune evasive strat-
egies using an integrative approach that combines clinical data, omics data and 
immunological data. 
Rational and scope of Part 2
Part 2 of this thesis shifts focus towards the development of another immune thera-
py, namely adoptive T cell therapy with TCR engineered cells (AT) for the treatment 
of TNBC. AT has been very successful in different blood cancers (OR for CAR-T cells 
in B cell malignancies: 90%28) as well as solid tumors (OR TCR-T cells in synovial 
sarcoma: 61% and in melanoma:  50%29)(reviewed in Chapter 5), but has not yet 
been tested clinically for the treatment of BC. Despite proven clinical efficacy, AT in 
solid tumors is challenged by lack of suitable target antigens, poor and non-durable 
responses and sometimes even toxicities14,28,30–32. In contrast to CAR-T cells, TCR-T 
cells have shown superior clinical efficacy and safety in solid tumors due to recogni-
tion of a variety of target antigens (i.e. extracellular as well as intracellular proteins 
presented via MHC), we opted for the latter form of AT in BC (chapter 6). New 
technologies, including TCR editing have been described which potentially further 
enhance safety and efficacy profiles of engineered T cells (described in Chapter 7). 
In extension, efficacy is sometimes compromised by the immune-suppressive TME, 
which can limit influx and migration, antigen presentation or suppression of tumor 
specific T cells (also reviewed in Chapter 5). In this regard, T cell evasive strategies, 
identified in Part 1 provide rational for combination that enhance the efficacy of AT in 
BC (discussed in Chapter 8). 
Study design and methodology: We studied gene and protein expression of 
target antigens for AT in TNBC and healthy tissues using large expression data 
sets and tissue micro arrays. We selected and applied a variety of in silico and 
laboratory tools that enable the identification of immunogenic epitopes including 
epitope predictions, immunopeptidome analysis of BC cell lines that overexpress 
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target antigens and in vitro binding assays. We identified TCRs using optimized 
protocols to enrich specific T cells from TILs or PBMC and tested their functionality 
and specificity in vitro. 
Thesis content in a nutshell
Chapter 2 introduces Part 1 by providing a detailed overview of the composition and 
the prognostic value of TILs among BC subtypes, and informs on the outcome of 
various immune therapy trials in different BC subtypes.
In Chapt 3 we have studied large patient cohorts of node-negative untreated BC and 
interrogated subtypes for the differential prognostic value of various immune param-
eters and the occurrence of immune evasive strategies using in silico techniques. 
In Chapter 4 we zoomed in on TNBC and have further delineated the prognostic 
and predictive value of spatial immune contextures (i.e., excluded, ignored and in-
flamed phenotypes) in untreated and anti-PD1 treated cancers. Furthermore, we 
performed in-depth analyses of distinct immune determinants and T cell evasive 
strategies among the different immunophenotypes using NGS data and multiplexed 
immune stainings. 
An introduction to Part 2 is provided in Chapter 5. Here we present an overview of 
new technologies, including various in silico and laboratory tools, to enable on the 
one hand selection and validation of target antigens, epitopes, and their correspond-
ing TCRs as well as to enable on the other hand choices of combinatorial approach-
es that counteract immune evasive mechanism.
In Chapter 6, we have applied these technologies and identified PCT2, a TNBC-spe-
cific target antigen with high and homogenous expression in tumor, but not healthy 
tissue. Using a variety of tools discussed in Chapter 5, we have identified safe and 
immunogenic epitopes and a corresponding TCR which may be further exploited for 
the development of AT for TNBC.
In Chapter 7, new technologies of TCR-editing that can further improve safety and 
efficacy of the identified TCR are discussed. 
The final Chapter 8 summarizes the main findings of both parts, and discuss how 
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There is an increasing awareness of the importance of tumor - immune cell interac-
tions to the evolution and therapy responses of breast cancer (BC). Not surprisingly, 
numerous studies are currently assessing the clinical value of immune modulation for 
BC patients. However, till now durable clinical responses are only rarely observed. 
It is important to realize that BC is a heterogeneous disease comprising several 
histological and molecular subtypes, which cannot be expected to be equally im-
munogenic and therefore not equally sensitive to single immune therapies. Here we 
review the characteristics of infiltrating leukocytes in healthy and malignant breast 
tissue, the prognostic and predictive values of immune cell subsets across different 
BC subtypes and the various existing immune evasive mechanisms. Furthermore, 
we describe the presence of certain groups of antigens as putative targets for treat-
ment, evaluate the outcomes of current clinical immunotherapy trials, and finally, we 
propose a strategy to better implement immuno-oncological markers to guide future 





APC  antigen presenting cell
APOBEC apolipoprotein B mRNA  
  editing enzyme, catalytic  
  polypeptide-like
BRCA1/2 breast cancer 1/2 
BCSS  breast cancer specific 
survival
CAF  cancer associated fibro- 
  blast
CCL  chemokine ligand
CD   cluster of differentiation
CMV  cytomegalo virus
CTLA4  cytotoxic T lymphocyte  
  associated protein 4
CR  Complete response
CXCL  CXC-motif chemokine  
  ligand  
DC  dendritic cell
DCIS  ductal carcinoma in situ
DFS  disease free survival
EBV  epstein-barr virus
ECM  extracellular matrix
ELF5  E75 like ETS transcription  
  factor 5
EMT  epithelial - mesenchymal  
  transition
GBP1  interferone induced gua 
  nylate binding protein 1
GRZM  granzyme
HER2  human epidermal growth  
  factor receptor 2
HERV-K  human endogenous retro 
  virus K
HLA  human leucocyte antigen 
HPV  human papiloma virus
HR  hormone receptor or  
  hazard ratio
hTERT  telomerase reverse tran 
  scriptase-
IDC  invasive ductal carcinoma
IDO1   indoleamine-pyrrole-  
  2,3-dioxygenase
IFN  interferon
IGK  immunoglobin kappa locus
IGLL5  immunoglobin lambda like  
  polypeptide 5
LAG3  lymphocyte activation  
  gene 3
MDSC  myeloid derived suppres- 
  sor cell
MEK  map kinase kinase
MFS  metastasis free survival
MHC   major histocompatibility  
  complex
MMTV  mouse mammary tumor  
  virus
MUC1  mucin 1
MV  measles virus
NK  natural killer cell
NO  nitric oxide
OCLN  occludin
OR  objective response or  
  odds ratio
OS  overall survival
PC  plasma cell
PD1  programmed cell death  
  protein 1
PDL1   programmed death ligand
PI3K  phosphoinositol 3-kinase
PR  progesteron receptor
RFS  relapse-free survival
ROS  reactive oxygen species
SD   stable disease
STAT1  signal transducer and  
  activator of transcription 1
TAA  tumor associated antigen
TAP  transport associated 
  protein
TIL  tumor infiltrating 
  leukocytes
TLS  tertiary lymphoid 
  structures
TGFB  transforming growth factor  
  -beta
TNBC  triple negative breast 
  cancer
TNFa  tumor necrosis factor  
  -alpha
Treg  Regulatory T cell





Cancer immunotherapy is a rapidly emerging field, which has proven successful 
in the treatment of various tumor types, such as lymphoma, melanoma, renal cell 
carcinoma, and non-small cell lung cancer 33. Initially, breast cancer (BC) has been 
considered a poorly immunogenic tumor type and has therefore not been extensive-
ly investigated for its susceptibility to immune therapies. During the past years, how-
ever, it became evident that certain cases of BC are strongly infiltrated by immune 
cells and that the presence of these immune cells has significant prognostic and 
predictive value. Although many studies are currently examining immune therapies 
for BC, still only a minority of patients appear to respond, and little is known about 
the underlying mechanisms of treatment efficacy. Thus, there is an unmet need to 
get better understanding of the interaction of breast cancer and the immune system 
in order to identify potential immuno-oncological prognostic and predictive markers 
as well as novel leads for effective mono or combination immune therapies. 
Genomics has improved our understanding of BC biology and revealed 4 intrinsic 
molecular subtypes: luminal A (resembling: ER+, PR+, HER2-, Ki67-), luminal B (re-
sembling: ER+, PR+, HER+/-, Ki67+), HER2 (resembling: ER-, PR-, HER2+), and 
basal-like subtype (resembling: ER-, PR-, HER2-). The classification of BC into sub-
types bears clinical relevance. For instance, in the treatment of the hormone recep-
tor (HR) positive subtypes (those that are positive for ER and/or PR) endocrine ther-
apy, including aromatase inhibitors or selective estrogen receptor mediators such 
as Tamoxifen, play an important role. HER2 over-expressing tumors are generally 
treated with HER2-targeting drugs such as trastuzumab and pertuzumab, whereas 
triple negative BC (TNBC, largely resembling the basal-like BC subtype) is mostly 
treated with standard cytotoxic therapies.
Notably, and the focus of the current review, these molecular subtypes also differ 
with respect to quantity and composition of tumor infiltrating leukocytes (TILs). In 
BC, an enormous number of studies have been performed in order to evaluate the 
prognostic and predictive values of TILs, and their specific subsets. Although mono-
nuclear cells can easily be identified by H&E-stainings upon routine diagnostics, this 
technique does not allow accurate assessment of different immune subsets. Im-
mune stainings have enabled the phenotypic distinction of various cell types, but are 
often limited to those markers for which well-characterized antibodies are available. 
Recent advances in immunogenomics have paved the way towards enhanced un-
derstanding of specific immune subsets and their interactions with tumor cells based 
on gene expression data 34–37. In addition, emerging DNA sequencing data has made 




ship with TILs and immune pathways. Here, we discuss TIL profiles, prognosis and 
prediction based on TIL subsets,  antigenicity, immune evasive mechanisms, and 
current immunotherapy trials. Finally, we propose a strategy to select and implement 
immune-oncological markers to improve therapy choices for BC patients.
2.2 Normal breast versus (pre)malignant breast tissues: quantity 
and quality of TILs 
Normal breast tissue
Immune cells in the healthy mammary gland form an active and dynamic barrier 
against microbes in the mucosal layer 38. In addition, immune cells take part in mam-
mary gland remodeling and are considered to play a role in cancer immune surveil-
lance 39. In normal breast tissue, one generally finds low numbers of leukocytes, 
including T cells (typically expressing the markers CD3, CD4 or CD3, CD8), B cells 
(CD20), macrophages (CD68) and dendritic cells (CD11c) 38. These immune cells 
are not found in interlobular stroma but are restricted to the lobules, where T cells 
directly associate with the epithelial layer 40. While frequencies of macrophages and 
CD4 T cells are rather constant, frequencies of CD8 T cells depend on hormonal 
changes and peak within the luteal phase of the menstrual cycle, coinciding with 
epithelial cell turnover 41. 
Pre-malignant breast tissue
BC formation is a multistep process, including premalignant stages of hyperplasia 
and ductal carcinoma in situ (DCIS) and the malignant stage of invasive ductal car-
cinoma (IDC) 42. The transition from normal breast tissue to malignancy typically 
goes along with an increased infiltration of leukocytes, including myeloid cells, B 
cells and cytotoxic CD8 T cells 40. First, in premalignant DCIS, an increased lym-
phocytic infiltration is observed 43, which is significantly higher in HER2+ and TN 
DCIS compared to HR+ DCIS 44. Numbers of neutrophils are significantly increased 
compared to normal tissue, however activated T cells represent the dominant lym-
phocyte population45, followed by B cells and the immune suppressive regulatory T 
cells (Tregs: CD4, CD25, FOXP3) 46. While in normal and premalignant BC the CD4/




 Malignant breast tissue
A common feature in IDC is a high overall quantity of TILs. Interestingly, high lym-
phocytic numbers relate to better prognosis and predict a favorable response to 
neo-adjuvant chemotherapy 49–51(see also sections 2.3 and 2.4). In fact, in highly in-
flamed tumors, TIL frequency was found to be a superior prognostic marker in com-
parison to HR status and lymph node involvement in patients with primary operable 
BC 47. Notably, characteristics of TILs vary across molecular subtypes of BC 52,53. The 
frequency of TILs is usually high in the more aggressive types of BC, including the 
ER- subtypes (HER2 and basal) as well as the highly proliferating luminal B subtype, 
but are low in the less aggressive luminal A subtype 54,55 (Figure 1A). Even though, 
the evaluation of overall TIL frequencies, based on H&E stainings, in feasible and 
clinically relevant 56,57, it is noteworthy, that TILs represent a heterogeneous collec-
tion of immune cells, and not all types or subsets of immune cells are associated with 
a favorable clinical outcome (Figure 1B and explained in more detail in section 2.3).
2.3 Prognosis of breast cancer based on TILs
Numerous studies have investigated the prognostic values of TILs and specific sub-
sets by means of H&E- and immune stainings, flow cytometry or analyses of gene 
expression. We evaluated 33 of such studies and schematically categorized different 
TIL subsets based on hazard ratios (HR) for ER- and ER+ BC (Figure 1B). 
2.3.1 Prognostic TILs in ER- breast cancer
ER- tumors typically show higher numbers of TILs when compared to ER+ tumors. 
Especially numbers of T- and B cells, macrophages and myeloid derived suppressor 
cells (MDSC) are higher in ER- compared to ER+ BC 53. 
Favorable outcome
Adaptive immune cells, including cells of T- and B cell lineages, are typically found 
in sites of prior, or ongoing immune reactions. High numbers of such lymphocytes 
are associated with a better prognosis in lymph node negative, primary BC patients 
including those with stages I-III 47,58–60. Moreover, numerous studies show that high 
frequencies of CD8 effector T cells and T helper type-1 gene signatures (Th1: IFNG, 




in ER- tumors  62 . In contrast, high numbers of Tregs in tumor tissue and blood are 
correlated with favorable outcome in ER- tumors, which may reflect the initiation of 
negative feedback since numbers of Tregs strongly correlate with those of CD8 T 
cells and are correlated with poor prognosis in the absence of CD8 T cells 62–64. B cell 
and plasma cell (PC: CD138) gene signatures are especially significant prognostic 
factors in ER- BC, but also in highly proliferating luminal B BC 54. Macrophages are 
enriched in basal-like BC and associate with survival according to immune stainings 
47,50,60. In agreement, myeloid and macrophage/dendritic cell signatures (oa. MHCII, 
CD11c, CD11b) were found to have overall prognostic value in BC according to large 
gene-expression cohorts 54,65. Notably, higher blood lymphocyte to monocyte ratio 
(LMR) correlates with overall survival (OS) in 1570 BC patients (HR: 1.63, 95% CI: 
1.07-2.49), in particular in TNBC patients (HR: 3.05, 95% CI: 1.08-8.61) 66. 
Unfavorable outcome
Frequencies of immature immune cells, such as MDSC (CD33) which can originate 
from monocytic or granulocytic lineages, are enriched in highly proliferating ER- tu-
mors 53, and intra-tumoral numbers of these cells are correlated with poor survival 
in ER- tumors 67. Elevated numbers of MDSCs are also found in peripheral blood 
of BC patients when compared to healthy controls 68. Strikingly, also in the blood 
compartment frequencies of MDSCs are associated with later stage tumors, meta-
static tumor burden, and are correlated with reduced survival 69,70. Also, numbers of 
intra-tumoral neutrophils (N, CD16) are associated with poor BC-specific survival 47, 
and meta-analysis revealed significant unfavorable prognosis in case of a high neu-
trophil to lymphocyte ratio (NLR, HR(OS): 2.03, 95% CI: 1.41-2.93) 71. High frequen-
cies of undifferentiated macrophages and alternatively activated, M2 macrophages 
(CD163) are inversely correlated with survival 67.
2.3.2 Prognostic TILs in ER+ BC
In comparison with ER- BC, less studies found significant correlations between im-
mune cell subsets and clinical outcome in ER+ BC. Overall, mostly innate immune 
cells cluster to the ER+, luminal A tumors and correlate with good prognosis 53.
Favorable outcome




are decreased in later tumor stages 74. Signatures of B cells including plasma cells, 
plasmablasts and immunoglobulin not only correlate with favorable outcome in ER-, 
but also ER+ tumors 20,32,40.  
Figure 1.  TIL frequencies and prognosis in ER+ and ER- BC: Violin plots based on average RNA ex-
pression of TIL gene signature [>100 leukocyte related genes, manuscript in preperation] on a log scale, 
per patient based on ER-status. (Data from NCBI’s Gene Expression Omnibus, accessions GSE2034, 
GSE5327, GSE2990, GSE7390 and GSE11121.) (A).  Leukocyte subsets which are significantly correlat-
ed (p<0.05) with overall survival, or metastasis free survival (*), in ER+ and ER- tumors. Hazard ratios 
of multivariant regression analyses are shown between brackets [HR]. Circle sizes are indicative of co-
hort-size (N), based on numbers of patients evaluated in one or more studies 13, 18-43. Studies include gene 
expression based analysis, immunohistochemistry and/or flow cytometry (B). 
Unfavorable outcome
Gamma delta T cells (Tγδ, TCRγ/δ) are more frequent in BC compared to other 
immunogenic tumors, such as melanoma, suggesting a unique role of these T cells 
in BC 77. Moreover, numbers of a subset of Tγδ cells, the so-called regulatory Tγδ, 
correlate with advanced cancer stages, lymph node involvement and numbers of 
FOXP3+ cells in ER+ BC, whereas numbers of this subset inversely correlate with 
those of CD8 T cells in these tumors 78. It is important to note that while Tregs are 
correlated with good prognosis in ER- tumors, these cells are strongly associated 
with adverse clinical outcome in ER+ tumors 62,64. Even though numbers of MDSC 




2.4 Prediction of breast cancer therapies based on TILs
Many studies show that standard neo-adjuvant therapies can recruit TILs and modify 
the tumor microenvironment. Vice versa, TILs, when present prior to therapy, were 
found to be predictive for clinical response to neo-adjuvant therapies.
2.4.1 Prediction of neo-adjuvant therapies based on TILs
Besides surgical resection and radiotherapy (RT), primary operable BC patients are 
frequently treated with neo-adjuvant chemotherapy (NAC) and/or targeted thera-
pies. It is of interest to note that numerous studies suggest that the immune system 
is required to boost the efficacy of NAC. Sequential treatment with anthracycline- or 
taxane-based drugs is a common form of NAC used to treat BC, with pathologi-
cal complete responses (pCR) ranging from 10 to 30%. NAC based on anthracy-
clines and taxanes can directly induce immunogenic tumor cell death, resulting in 
increased antigen presentation. Moreover, NAC was found to induce inflammatory 
pathways in tumor associated fibroblasts, such as interferon, Wnt and TGFβ sig-
naling pathways 79, which can enhance recruitment of TILs. Consequently, immune 
gene signatures have been revealed to predict the response to NAC across various 
studies, regardless of molecular subtypes or treatment regime 54,80,81. Also, high TIL 
frequencies (>60%), as assessed by H&E stainings were predictive for response 
to NAC82. In fact, a 10% increase in TIL frequencies resulted in 16% increase in 
pCR rates in TNBC (OR: 1.16), 13% in HER2 (OR: 1.13), and 33% in ER+/ HER2- 
BC (OR: 1.31). In the latter subtype no survival benefit was noted, which may be 
attributed to differences in TIL composition (as explained in more detail in sections 
2.3.1 and 2.3.2). The predictive value of TILs in the setting of NAC is mainly attribut-
ed to high numbers of CD8 T cells (odds ratio (OR) for pCR: 1.59-3.36, 83,84) but 
also the presence of follicular T helper cells (Tfh: CD200, CXCL13), were found to 
have predictive value in ER- (OR(pCR): 1.34-1.85) as well as ER+ (OR(pCR): 2.52) 
BC patients, across different studies, using both immune stainings and genomic 
approaches 67,73,83. Vice versa, chemotherapy can change the immune cell compo-
sition in tumor tissue and blood. For example, within 2 weeks after NAC, B-, T- and 
NK cells were found significantly depleted from peripheral blood compared to pre-
treatment levels, with numbers of B and CD4 T cells remaining low up to 9 months 
post chemotherapy 85, whereas numbers of MDSCs were increased 69. Numbers of 
intra-tumoral CD68 macrophages were found significantly decreased to NAC, while 
those of intra-tumoral CD8 T cells were increased compared to pre-NAC frequencies 
50,69. Strikingly, high intra-tumoral numbers of CD3, CD4 and CD20 as well as high 




of subtype or clinical parameters (OR(pCR): 17.84 50). In ER- tumors, pre-therapy 
T- and B cell signatures were found to predict long-term (> 6 year) outcome to anth-
racycline-based chemotherapy (OR(pCR):6.33 86). 
Similar to NAC, RT can also induce immunogenic cell death, antigen release and lo-
cal inflammation, and consequently evoke an innate and adaptive immune response 
directed against the tumor 87. Interestingly, in an ER-, HER2+ patient, who showed a 
clinical complete response following neo-adjuvant (paclitaxel) and RT, the production 
of Th1-type cytokines by tumor-specific T cells was enhanced compared to pre-treat-
ment 88. Immune responses may also predict clinical responses to endocrine therapy 
89,90. In example, OS of post-menopausal women treated with aromatase inhibitors, 
which block the conversion of androgens into estrogens, is correlated with high 
numbers of TILs, in particular high numbers of Tregs 91.  In contrast, treatment with 
tamoxifen (an ER antagonist) shifts immune response from Th1- towards Th2-type 
T cell responses in an estrogen-independent manner, and may promote immune es-
cape 92. Treatment with trastuzumab, a humanized antibody directed towards HER2, 
is at least in part dependent on the immune system as this treatment induces influx 
of T cells, macrophages and NK cells into tumor tissue and promotes cell-mediated 
cytotoxicity 93. Vice versa, pre-existing lymphocytic infiltrate can predict response to 
trastuzumab treatment 94,95, altough clinical studies provide somewhat contradictive 
data. While in certain trials higher TIL frequencies 7 or high expression of TIL gene 
signatures 96 at diagnosis were significantly associated with good response when 
treated with trastuzumab in combination with CT, in another large clinical trial the 
presence of TILs was associated with survival in patients treated with chemother-
apy only, but not in patients treated with CT plus trastuzumab 97. Interestingly, in 
the same study expression of genes related to immune function, did correlate with 
survival in the CT plus trastuzumab treated group 98, suggesting that particular TIL 
subsets, rather than bulk TIL predict response. These conflicting results between dif-
ferent studies, may be explained by differences in treatment regime and HR status of 
patients 99, because the latter correlates with CT response as well as TIL frequency 
and composition, potentially favoring that patients treated with trastuzumab should 
be stratified according to HR status. Further research is required to better define the 
predictive value of particular TIL subsets in this patient group. 
Overall, the above findings suggest that standard care of treatments can modulate 
the tumor microenvironment and may sensitize tumors towards immune therapies. 
In fact, combination of RT and NAC with immune therapies has already shown prom-
ising results in mouse models of BC, and is currently investigated in a number of 




2.4.2 Prediction of immune therapies based on TILs
Thus far, immunotherapeutic approaches to treat BC include: peptide vaccines; au-
tologous transfer of T cells, NK cells or DCs; and application of checkpoint inhibi-
tors. An overview of these treatments is given in Table 1. Vaccinations in BC have 
been focusing mainly on targeting the over-expressed HER2/neu antigen, for which 
successful treatment has been achieved in DCIS, usually resulting in lesion shrink-
age along with activation of HER2-specific CD8 T cells 103–105. In later stage tumors, 
however, at best stable disease (SD) has been achieved using similar approaches. 
Adoptive transfer of autologous HER2-specific T cells resulted in the killing of BC 
cells that were metastasized to bone marrow, but these T cells were unable to pen-
etrate and resolve liver metastases 106,107. In contrast, adoptive transfer of allogeneic 
T cells or NK cells to metastatic BC patients (all subtypes) did not result in T cell 
persistence and frequently led to graft versus host disease 108,109. Promising clinical 
responses have been observed for checkpoint inhibition in the advanced metastatic 
BC setting. For example, blockade of CTLA-4 (Tremelimumab) has led to SD for 
>12 weeks in 42% of heavily pre-treated ER+ patients 110. Even better responses, 
including a few complete responses and several partial responses, were observed 
upon treatment with a PD-1 blocking antibody (Pembrolizumab) in TNBC patients 
with PD-L1-positive tumors in 2 trials (objective response (OR): 18.5%, 111; OR: 23%, 
112). Combinations of CTLA-4 (Tremelimumab) and PD-L1 (Durvalumab) blockade 
even reached OR in 43% of stage IV, TNBC patients, however, no OR was observed 
in any of the 11 HR+ patients, 113 which may be due to low numbers of CD8 T cells 
in these tumors (Figure 3). In contrast, blockade of PD-L1 (antibody not specified) 
in a small group of 4 stage IV BC patients (unknown HR status) did not result in any 
clinical response 114. Notably, in that study, PD-L1 expression had not been assessed 
prior to PD-L1 treatment, which may have contributed to these contradicting results. 
Another large trial with a PD-L1 blocking antibody (Avelumab), in 168 BC patients, 
which were not selected for BC subtype nor PD-L1 expression, resulted in a low 
OR of 4.8%, including 1 CR and 7 PR 115. When evaluating BC subtypes in that 
study, TNBC patients had an OR of 8.6% while HR+ patients had an OR of 2.8%. 
Even though >10% PD-L1 expression on immune cells in TNBC tumors correlated 
with response, interestingly, there was no overall association of PD-L1 expression 
and OR 116. Due to the dynamic nature of PD-L1 expression (explained in section 
2.5), we propose to take caution when using this molecule to stratify BC patients 
for treatment with checkpoint inhibitors. The presence of TILs, in particular CD8 T 
cells, and (co-)expression of checkpoint molecules on these cells may serve as a 
more discriminatory marker than tumor cell PD-L1 expression. In fact, high stromal 
TIL numbers were significantly correlated with a better response to PD-1 blockade 




static TNBC (OR: 39.1% above median stromal TIL; OR: 8.7% below median stromal 
TIL), while  PD-L1 expression did not add to the response prediction in that cohort 117. 
Promising results have also been observed when combining checkpoint blockade 
with standard chemotherapies in the neo-adjuvant, as well as the advanced disease 
setting of TNBC: Upon combination of neo-adjuvant  paclitaxel and PD-1 blockade 
(Pembrolizumab), an impressive OR of 71% was observed in stage II/III TNBC pa-
tients, and an OR of 28% was seen in HR+ patients, which were both significantly 
increased when compared to paclitaxel monotherapy (OR: 19% and 14% in both 
patient groups, respectively) 118. In addition, combination of nab-paclitaxel and PD-
L1 blockade (Atezolizumab) in metastatic TNBC reached comparable results (OR: 
70%) independent of PDL-1 status 119. Notably, the OR-rates where higher in early 
lines of therapy in patients with a lower disease burden, reaching 11% CR and 78% 
PR in patients with one lesion, in contrast to 0% CD and 43% PR in patients with 
3 lesions. When treating mainly HR+ metastatic BC with a combination of LAG3Ig 
fusion protein (IMP321) with paclitaxel, an OR of 50% was achieved which was 25% 
higher compared to a historical paclitaxel treatment results 120. These data strongly 
encourage the rational of combination therapies, particularly in BC where initial TIL 
numbers are low (HR+) and sensitization of the tumor micro environment may be 
required for effective immune therapies (Figure 4).
At the moment, an increasing number of clinical studies are focusing on immune 
therapies for BC of various subtypes. A main category of immune treatments is 
represented by (combinations of) antibodies blocking the checkpoints PD-1, PD-
L1, CTLA-4, and LAG-3. In addition to the checkpoint blockade studies mentioned 
above, another 91 trials are currently being scheduled (blockade of PDL-1: 13x; 
CTLA-4: 10x; PD-1: 62x; LAG3: 6x, according to clinicaltrials.gov). In addition to 
checkpoint blockers, vaccine studies are performed directed against over-expressed 
antigens other than HER2, such as hTERT, surviving and p53. And finally, adoptive 
transfer studies with T cells have started, either those with T cells engineered with 
a Chimeric Antigen Receptor (directed against: HER2 (3x), EpCAM, ROR1, MUC1 
and CD133) or a T cell Receptor (directed against: survivin or Cancer Germline 





Type of immune therapy Target Stage / type Patients Clinical outcome
DC vaccination
Her2 peptides (MHCI and II) 103 HER2 0 / HER2 11 PR: 64%
Her2 peptides (MHCI and II) 104, 105 HER2 0 / HER2 27 PR:88%,CR:40%(ER-); 
5.9%(ER+)
autologous APC + Her2/neu cDNA 121 HER2 IV / HER2 18 PR: 5%, SD: 16%
autologous DC 122 II,IIIA / ER-, PR- 31 PD: 100%
wt p53 peptide (MHC II) 123 P53 IV 26 SD: 30%
Vaccination (not DC)     
Mam-A cDNA 124 Mam-A IV 7 NA
E75 Her2 peptide (HLA-A2/A3) 125 HER2 0 / HER2 182 DFS: 94.3%
MDA-MB-231 (CD80+, HLA-A2, 
HER2) cell line 126
HER2 IV 30 SD: 30%
AE37 Her2/neu peptide (MHCII) 127 HER2 0 15 NA
Checkpoint inhibitors     
anti PD-L1 (not specified) 144 PDL1 IV 4 PD: 100%
tremelimumab 110 CTLA4 IV / ER+ 26 SD: 42%
pembrolizumab 111 PD1 IV / TNBC 27 CR: 2.7%, PR: 15%, SD:26%
pembrolizumab 112 PD1 IV/TNBC 52 CR: 4% PR: 19%, SD: 17%
pvelumab 115 PDL1 II/IV 168 CR:0.6%  PR: 4.8% SD:24%
pembrolizumab + paclitaxel 118 PD1 II, III/ Her2- 69 CR: 71.4% (TNBC), CR: 28% 
(HR+)
durvalumab + tremelimumab 113 PDL1, 
CTLA4
IV/ ER+, TNBC 18 PR: 43% (TNBC), 0% ER+
atezolizumab + nab-paclitaxel 119 PDL1 IV TNBC 32 CR: 4,2% PR:66.7% SD: 
20.8%
Adoptive Transfer of immune cells     
autologous T cells 106 HER2 IV / HER2 1 NA
allogenic T cell mix IV 9 PR: 56%




IV / HER2+/- 23 SD: 27%
allogenic NK cells 109 IV 6 NA
Other therapies     
oxidized mannam MUC1 128 MUC1 II / MUC1+ 31 NA
zoledronate (ydT cell agonist) + IL2 129 IV 10 PR: 10%, SD: 20%
IMP321 (LAG3Ig fusion protein)  + 
paclitaxel 120
MHCII IV 30 PR: 50% SD:40%
Table 1. Overview of immune therapy clinical trials in BC. NA, not assessed; PR, partial response; 
CR, complete response; SD, stable disease; PD, progressive disease; DFS, disease free survival; DTH, 




2.5 Immunogenicity of breast cancer knows several flavors
Immunogenicity of tumor tissue determines the initiation of an anti-tumor adaptive 
immune response, and depends on various factors, including the quantity and qual-
ity of TAA and their presentation to infiltrating immune cells. TAAs are typically cat-
egorized in different groups of antigens, including shared antigens which are gen-
erally over-expressed in tumors, but not restricted to malignant tissues (and also 
expressed by normal tissues). Some shared antigens, such as oncoviral antigens 
and Cancer Germline Antigens (CGAs), are predominantly expressed in tumors and, 
in case of CGAs, also in immune privileged tissues of the germline. Besides shared 
antigens, TAAs also include non-shared antigens, such as tumor-specific neo-anti-
gens, which derive from mutated proteins, and are absent in normal tissues.
Most of these groups of TAAs have been exploited for their use as immunotherapeu-
tic targets in many different tumors. In BC most experience has been gained with the 
targeting of over-expressed antigens. Even though over-expressed antigens are not 
tumor-specific, cancer vaccines directed towards such antigens, including HER2, 
MUC1, and hTERT, could induce partial regression and induce immune responses 
against these antigens in a number of BC patients without major side effects (re-
viewed in 130,131). Virus specific DNA can drive tumor formation and lead to expres-
sion of oncoviral antigens. Virus specific DNA (EBV, HPV and MMTV) is significantly 
more frequently detected in BC compared to normal breast tissues 132. For instance, 
expression of human retrovirus type K (HERV-K) is enriched in BC, including BC 
cell lines, and antibody titers are significantly increased in women with DCIS and 
IDC when compared to healthy controls 133. Also, Measle Virus (MV) was detected in 
64% of BC including DCIS, and its expression correlated with younger age and lower 
grade tumors 134. Notably, human cytomegalovirus (CMV) is expressed in 100% of 
primary BC specimens and 95% of lymph node metastases 135, while it is generally 
not expressed in normal tissues 136. Although in general the presence and reported 
immunogenicity of viral antigens is evident, the therapeutic potential of this class of 
TAAs in BC is not clear, nor have these antigens yet been targeted in BC patients. 
CGAs have not yet been targeted frequently either, while the majority of BC express 
at least a single CGA 137. Although CGAs are expressed throughout all tumor stages, 
including DCIS and all histotypes 138, expression levels and number of expressed 
CGAs are significantly increased in high grade and ER- BC (highest in basal-like 
BC) (Figure 2A). Interestingly, especially TNBC patients and BRCA carriers often 
co-express multiple CGAs 139,140. Besides their high and tumor-specific expression 
of at least some CGAs, these antigens represent therapeutically relevant target an-
tigens since they have been reported to elicit humoral immune response and were 




CGA+ BC have demonstrated enhanced antibody titers against these antigens, and 
CGAs, have been reported to be associated with increased EMT, genomic instability, 
angiogenesis and tissue invasion in BC 141–143. Not surprisingly, expression of these 
CGAs is often linked to adverse outcome. With respect to neo-antigens, expression 
of these antigens is governed by the mutational load of tumors. Compared to other 
cancer types, BC has an average mutational load of 1 somatic mutation per Mb, 
which ranks these tumors among the lower half of a large series of different human 
cancer types 144. A mutational load of 10 somatic mutations per Mb (= 150 non-syn-
onymous mutations in all expressed genes) is considered sufficient to elicit a T cell 
response in melanoma 145. This suggests that the overall chance of T cells recog-
nizing neo-antigens in BC is rather low. Within BC, however, the median mutational 
load increases upon higher tumor grades, and the mutational load is significantly 
increased in ER- subtypes (highest in Basal-like BC), compared to ER+ subtypes, 
regardless of BC histotypes 146, (Figure 2B). These findings suggest that more ag-
gressive, ER- BC may be susceptible for the immunological targeting of neo-anti-
gens. Besides the number of mutations, some mutational signatures were found to 
be more immunogenic than others. The most prevalent mutational signatures in BC 
are age-, APOBEC- and BRCA1/2-related signatures 144. APOBEC3B (A3B) expres-
sion is enhanced in ER-, HER2+ subtypes, and correlates with lymph node metasta-
sis 147 and poor prognosis 148. Interestingly, we have shown previously that APOBEC 
signatures may create positively charged, neo-antigens, which are associated with 
increased T cell infiltration in ER+ BC 149. A3B deletion, on the other hand, leading to 
hyper-mutation, correlates with IFNy/STAT1 expression and immune cell signatures 
147. The exact mechanism and role of A3B and APOBEC mutagenisis in BC immuno-
genicity requires further research. 
Figure 2. Antigen expression across BC subtypes.  Violin plots show average CGA gene expression 
on a log scale, per patient, based on  molecular subtypes. Differences in CGA frequency per molecular 
subtype are significant (p<<0.0001, Kruskal Wallis test). CGA genes list was derived from CT Database 
and include CGA genes that were available on Affymetric U133a chip, data from GSE2034, GSE5327 (A). 
Violin plots show the total number of predicted neo-antigens 149 per patient, based on molecular subtypes.




2.6 Immune evasion of breast cancer counteracts effective 
therapy
High expression levels of tumor associated antigen (TAA) in late stage and HER2+, 
ER- BC or TNBC, and high frequencies of TILs in these subtypes do not correlate 
with each other 150, suggesting that either not all TAAs are equally immunogenic and/
or that these tumors have undergone immune editing. The latter generally refers to 
the shaping of tumor antigenicity under the selective pressure of effector immune 
cells, and ultimately gives way to the establishment of immune evasive mechanisms 
151,152. Such immune evasive mechanisms may include down-regulation of antigen 
presentation, lack of immune effector cells, enrichment of immune suppressor cells, 
and up-regulation of checkpoint molecules 34,35. 
Antigen presentation
Critical for the recognition of tumor cells by T cells is that peptides derived from TAAs 
are presented on human leukocyte antigen (HLA) molecules expressed on the sur-
face of tumor cells or antigen-presenting cells. In fact, expression of genes related to 
the HLA-A antigen presentation pathway correlates with expression of genes related 
to T cells, and was found to be most significantly associated with survival within 
TNBC patients 153. Especially higher grade BC often (30-40% of tumors) down-reg-
ulate classical HLA-A, HLA-B, HLA-C molecules, which are required for the activa-
tion of CD8 T cells, and up-regulate non-classical HLA-E, HLA-F, HLA-G molecules, 
which may promote immune escape 154–156. Besides HLA-A, expression of trans-
port-associated proteins (TAP1/TAP2), which are required for proper antigen load-
ing, is also down-regulated in high-grade BC 157. TAP1/TAP2 down-regulation, how-
ever, is independent from HLA-A, B, C down-regulation 158, pointing to lack/absence 
of redundancy of various components of the HLA antigen presentation pathway with 
respect to immune escape. Besides downregulation of antigen presentation, mu-
tations in antigen presentation (B2M) and IFN response genes (JAK1/2) pathways 
may provide yet another mechanism of immune escape. Mutations in JAK1/2 can 
lead to primary as well as acquired resistance to checkpoint blockade159,160 and po-
tentially other immune therapies. While JAK1/2 mutations affect only a minority of 
primary BC, and only truncated mutations (1.3% of BC) are associated with poor 
prognosis159, BC metastases were found to have acquired additional JAK/STAT driv-
er mutations 161.
Immune effector and suppressor cells
The frequency of clonally expanded, activated T cell is decreased in IDC compared 




and/or that there is a lack of T cell recruitment or active suppression. In general, 
exclusion from tumor tissue or compromised activity of intra-tumoral CD8 T cells 
may in some cases be the direct consequence of aberrant expression of chemok-
ines, adhesion molecules and/or extracellular matrix components (ECM), which to 
our knowledge has not been investigated yet in BC. There is increasing evidence 
that oncogenic pathway alterations may contribute to T cell exclusion or comprised 
activity152. PI3K pathway alterations are the most common driver mutations in BC, 
affecting 49% of luminal A tumors while affecting only 7% of basal like BC162. Inter-
estingly, PTEN loss, which was found to correlate with a lack of TILs in melanoma 
163, frequently occurs in basal-like BC (35%)162 and may contribute to heterogeneity 
with respect of TILs in this BC subtype.  In addition, in  TNBC, a lack of T cells is as-
sociated with RAS/MAPK pathway activation 164. Exclusion or compromised activity 
of CD8 T cells, in other cases, may also be the indirect consequence of enhanced 
presence of M2 macrophages, MDSC, Tregs and/or cancer associated fibroblasts 
(CAFs) 31. CAFs can promote angiogenesis and/or endothelial to mesemchymal 
transition (EMT), and release suppressive cytokines, such as IL1, IL6 and TGFβ, 
which can drive the formation of immune suppressor cells 165,166. In BC, immune sup-
pressor cells, including MDSC and M2, can promote tumor growth and metastasis 
and suppress T- and NK cell function by releasing suppressive mediators, such as 
IL10, IDO1, reactive oxygen species (ROS) and nitric oxide (NO) 167,168. Enhanced 
recruitment of MDSC is considered to be related to increased expression of ELF5 
and CCL2 in ER- BC, and enhanced IFN-signaling was found to induce immune 
suppressive activities of MDSC 169. Tregs are recruited by CCL5 and CCL22, which 
are produced by CD8 T cells and DC 170. Next to inhibition of CD8 T cells, Tregs can 
directly promote BC metastasis in a paracrine manner 170. 
Checkpoint molecule
As a consequence of an ongoing adaptive immune response, CD8 T cells, but also 
their target cells, up-regulate the expression of a number of immune checkpoint 
molecules, which slow down and ultimately inhibit active tumor killing by T cells. 
PD-L1, for instance, is expressed in a quarter of all BCs and high expression levels 
correlate with poor OS across all subtypes 171. PD-L1 expression is particularly high 
in inflammatory BC (IBC, defined by symptoms resembling an inflammation, mostly 
ER-), and correlates with T- and B- cell signatures, most significantly those cover-
ing cytotoxic T cells, interferon and TNFα pathways 172. Early BC stages, such as 
DCIS do not yet express PD-L1, however, in triple negative DCIS, APCs do already 
show strong PD-L1 expression 46. Besides acquired expression of PD-L1 by the 
inducers IFNα/β or IFNγ, which are well-recognized products of activated immune 




and 40% of BC, respectively, were found to provide inherent expression of PD-L1 
173. Moreover, EMT was found to induce PI3K and MEK-dependent up-regulation 
of PD-L1 in BC 174. PD-L1 expression in BC is accompanied by expression of other 
immune suppressive checkpoints, like IDO1 and TGFb, as well as the expression of 
T cell co-inhibitory receptors, such as PD-1, CTLA-4, TIM-3 and LAG-3 172,174. PD-1 
expression is commonly up-regulated after T cell activation and PD-1 positive T cells 
can be detected in blood of early stage BC patients, while peripheral changes in the 
expression of other checkpoint molecules such as CTLA-4 are not observed 175. 
Figure 3. Schematic illustration of immunity and evasive mechanisms in BC. BC subsets are cat-
egorized according to hormone receptor ER and PR (blue) or HER2 (pink) expression of tumor cells 
(brown). Antigenicity (ao. CGAs and neo-antigens) increases from luminal to basal type BC. Overall TIL 
quantity (gray background) increases from lumA to basal type BC, and its increase is related to tumor cell 
proliferation (Ki67). With respect to TIL quality, lumA tumors have relatively more innate immune cells, 
whereas the highly proliferating lumB, her2 and basal BCs are enriched for adaptive immune cells and 
immune suppressor cells. In particular, basal BC is enriched for exhausted CD8 T cells.
Within tumors, T cells positive for PD-1 are generally restricted to tertiary lymphoid 
structures (TLS), which are present in tumor stroma and composed of B- and T 
cells. TLS are often representative of a strong and ongoing immune response, and 




pression of PD-1 and LAG-3 tends to be associated with good prognosis. PD-1 and 
LAG-3 positive TILs were found in 30% and 18% of BC, respectively, and 15% of 
tumors were double positive for these markers, most likely indicating the presence 
of exhausted T cells 177. Checkpoint molecules are not only up-regulated on CD8 T 
cells as PD-1 and TIM-3 were also found to be up-regulated on CD4+ Tfh cells in 
BC, which was associated with both a reduced CXCL13 production and a reduced 
capability of stimulating B cells 178. Interestingly, in metastatic lesions, only 5% and 
3% were found positive for the PD-1 and PD-L1, respecievely, arguing that other 
immune evasive mechanism may be more dominant in advanced diseases 179.
2.7 Future therapies should combine tumor sensitization and T 
cell treatments 
Here we propose a strategy that implements immune-oncological markers to better 
select immune therapies in BC subtypes, and rationalize whether or not there is a 
requirement for sensitization for immune therapies based on our current understand-
ing of BC’s immune evasion and immunogenicity. In Figure 4, we have distinguished 
ER+ and ER- BC, and described steps in selecting (combination) immune therapies: 
Across BC subtypes, ER+ tumors, in particular luminal A BC, are the least immuno-
genic since they have the lowest number of TILs and the lowest levels of expression 
of CGAs and neo-antigens (Figure 3). Because of the low abundance of antigen, 
immune therapies targeting TAAs in ER+ BC require extensive screening for pre-de-
fined antigens, which is costly and time consuming. Therefore, immune therapies 
using checkpoint inhibition, which do not directly target TAAs, but rather TILs, may 
show more potential in ER+ BC, since the presence of TILs can easily be assessed 
by H&E or immune stainings of routine biopsies. Thus far checkpoint blockade as 
monotherapy in ER+ tumors has resulted in SD at best (see section 2.4.2). In a 
subset of ER+ BC patients with deficiency in DNA mismatch repair (MMR) genes 
180, mutational load may represent an independent parameter for therapy selec-
tion. In general, however, we argue that the presence of TILs rather than mutational 
load serves as a robust marker for patient stratification in BC. Even though TILs in 
ER+ BC are generally scarce and composed of innate rather than adaptive immune 
cells, it is important to note that there exists significant heterogeneity with respect 
to quantity and quality of TILs (own observations; manuscript in preparation). The 
presence of effector CD8 T cells, and the expression of immune checkpoint mole-
cules on these T cells are indicative of an antigen-initiated immune response, which 
is anticipated to robustly predict success of checkpoint blockade in patients with 




(which reflects an ongoing immune response) should be assessed in the first step 
when designing therapies (Figure 4, step1). In case CD8 T cells are absent one 
could opt for combinitation therapies since checkpoint blockade with NAC was found 
to increase TIL levels 181 and to enhance the CD8/Treg ratio (see section 2.4.1), 
may further enhance treatment efficacy in ER+ BC. In fact, such combinations have 
shown to increased pCR rates by 13-25%, when compared to NAC monotherapy 
(Table 1). The immunogenicity of tumors may also be increased by epigenetic drug 
treatment, including DNA-methyltransferase and/or histone deacetylase inhibitors, 
which were found to promote expressions of CGAs, MHC-I as well as co-stimula-
tory molecules in particular in tumor cells 182,183. A few clinical studies are currently 
examining the combination of epigenetic drugs and checkpoint inhibitors in ER+ BC 
184. Even though results have not yet been published, combining cytotoxic therapies 
and/or epigenetic drugs with checkpoint inhibitors should be considered interesting 
strategies to treat ER+ BC.
In contrast to ER+ tumors, ER- tumors (HER2, TNBC) are intrinsically more immuno-
genic. Among all BC subtypes, TNBC bear the highest numbers of T cells, which are 
accompanied by the highest frequencies of neo-antigens and CGAs, and intra-tu-
moral CD8 T cells are often present with an exhausted T cell phenotype (Figure 3). 
Thus, TNBCs may represent a subtype of BC most sensitive to immune therapeutic 
interventions. However, antigenicity does not always predict response to checkpoint 
inhibition 185. Even though clinical trials have resulted in higher response rates to 
checkpoint blockade in TNBC tumors when compared to ER+ tumors (Table 1), the 
majority of metastatic patients, however, does not show any clinical benefit to check-
point blockade as monotherapy. This lack of response may be due to heterogeneity 
with respect to expression of checkpoint molecules or numbers of TILs. Indeed, high 
numbers of TILs and CD8 were predictive for response to checkpoint inh as first-
line and second-line (following irradiation and chemotherapy) treatment for metstatic 
TNBC  117,186. Therefore, also in ER- tumors, the presence of CD8 T cells should be 
assessed first. Most likely T cells are present. In case checkpoint molecules are 
present, one could again opt for therapy with checkpoint inhibitors. Multiple check-
point molecules should be evaluated, since ER- tumors often co-express these mol-
ecules, which may prevent an effective monotherapy-approach. Indeed, the combi-
nation of durvalumab and tremelimumab resultated in an about 2-fold increased OR 
of 43% in TNBC patients 113 when compared to monotherapy approaches. In case 
these checkpoint moelcules are not expressed, but immune suppressor cells are 
present (assessed in step 3), inhibitors of these suppressor cells provide a therapeu-
tic option 187,188. In some cases CD8 T cells are absent. An underlying reason for CD8 




be lack of or a compromised antigen presentation by tumor cells and/or activation 
of oncogenic pathways. When CD8 T cells are absent, we suggest to assess MHC 
expression (which reflects capability of antigen presentation). In case MHC class 
I is expressed, then in the next steps assessments (of TAAs and corresponding T 
cells) inform on the option to implement adoptive therapy of T cells. In case MHC 
class I is not expressed, one could opt for therapy with PI3K and MEK-inhibitors that 
are found to up-regulate expression of MHCI and PD-L1 in TNBC. In more general 
terms, epigenetic drugs, RT and/or NAC are other therapeutic options to sensitize 
tumors for T cell treatments, such as adoptive T cell therapy.
Figure 4. Strategy to optimally implement immuno-oncological markers to guide selection of ther-
apies for ER+ and ER- BC patients. Thick arrows indicate the most likely path. Strategies are explained 
in more detail in section 2.7.
In conclusion, BC subtypes are heterogenous with respect to quantity and quality 
of TILs, occurrence of immune evasive mechanisms, and antigenicity. Therefore all 
these factors should be assessed and taken into account when designing and se-
lecting optimal (combination-) immune therapies for a selected group of BC patients.
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Purpose: In breast cancer (BC), response rates to immune therapies are generally 
low and differ significantly across molecular subtypes, urging a better understanding 
of immunogenicity and immune evasion.
Experimental Design: We interrogated large gene-expression datasets including 
867 node-negative, treatment-naïve BC patients (micro-array data) and 347 BC pa-
tients (whole-genome sequence and transcriptome data) according to parameters of 
T cells as well as immune micro-environment in relation to patient survival.
Results: We developed a 109 immune-gene signature that captures abundance of 
CD8 TILs and is prognostic in basal-like, her2 and luminal-B BC, but not in luminal-A 
nor normal-like BC. Basal-like and her2 are characterized by highest CD8 TIL abun-
dance, highest T cell clonality, highest frequencies of memory T cells, highest anti-
genicity, yet only the former shows highest expression level of immune and meta-
bolic checkpoints and highest frequency of myeloid suppressor cells. Also, luminal-B 
shows a high antigenicity and T cell clonality, yet a low abundance of CD8 TILs. In 
contrast, luminal-A and normal-like both show a low antigenicity, and notably, a low 
and high abundance of CD8 TILs, respectively, which associates with T cell influx 
parameters, such as expression of adhesion molecules.
Conclusion: Collectively, our data argue that not only CD8 T cell presence itself, 
but rather T cell clonality, T cell subset distribution, co-inhibition and antigen pre-
sentation reflect occurrence of a CD8 T cell response in BC subtypes, which have 
been aborted by distinct T cell suppressive mechanisms, providing a rational for 
subtype-specific combination immune therapies. 
Translational relevance: 
In breast cancer (BC) current immunotherapy trials focus on checkpoint inhibition in 
basal-like BC, and despite high levels of CD8 TILs, clinical benefit is rarely observed. 
Here, we show that basal-like BC is characterized by high antigenicity and T cell 
clonality, prerequisites and markers of an anti-tumor CD8 T cell response, but also 
by enhanced expression of immune and metabolic checkpoints and the presence of 
myeloid-derived suppressor cells, which represent actionable targets for combination 
therapies. Moreover, we observed high antigenicity and T cell clonality in her2 and 
luminal-B subtypes, yet these subtypes show distinct T cell evasive mechanisms, 
indicating that at least a subgroup of her2 and luminal-B patients may benefit from 
biomarker guided (combination) immune therapies. Lastly, luminal A and normal-like 
subtypes, do not express genes related to a CD8 T cell response, which may instruct 





Numerous immunotherapy approaches are currently being exploited for a variety 
of human malignancies, including hematologic as well as solid tumors. These ap-
proaches generally include oncolytic viral therapy, cancer vaccines, adoptive T cell 
therapy and application of checkpoint inhibitors (CI). Particularly the latter two have 
demonstrated impressive objective response rates (OR) of up to 80%, including sev-
eral complete responses in advanced disease stages 189,190. 
Breast cancer (BC) has initially been considered poorly immunogenic due to its low 
average mutational burden when compared to other tumor types 144. More recent-
ly, it has been acknowledged that some breast tumors are extensively infiltrated 
by immune cells 8 and it became evident that density of tumor infiltrating lympho-
cytes (TIL), in particular CD8 T cells, has prognostic value and predicts response to 
neo-adjuvant chemotherapy as well as immune modulating therapies 5,84,191–193. Build-
ing on the revisited immunogenicity, several studies are currently exploiting cancer 
vaccines, adoptive T cell therapies or CI for the treatment of BC 194. Unexpectedly, 
ORs remain variable, and generally do not exceed 20% for CI mono-therapy 195. 
BC is a heterogeneous disease comprising several histological and molecular sub-
types. The most well recognized subtypes include luminal-A and normal-like (largely 
resembling the histological phenotype: ER+, PR+ and HER2-), luminal-B (ER+ PR+ 
KI67hi and/or HER2+), her2 (ER-, PR-, HER2+), and basal-like subtype (largely re-
sembling the triple negative (TN) phenotype: ER-, PR-, HER2-) 196,197. This subtype 
classification has clinical relevance with respect to prognosis and choice of targeted 
therapies 197. Notably, it has been observed that TN tumors respond better to CI 
treatment when compared to ER+ BC 113. Nevertheless, responses to immune thera-
pies are not restricted to TNBC patients, as it has been reported that a metastatic lu-
minal-A BC patient showed complete regression following adoptive T cell therapy 198. 
Immune parameters that can be decisive towards an effective anti-tumor response, 
such as those reflecting immunogenicity as well as occurrence of T cell evasion, are 
poorly characterized in case of BC and thus critical factors determining tumor immu-
nogenicity poorly understood. Tumor immunogenicity, which is the extent to which 
adaptive immune responses are triggered, depends on multiple factors including the 
expression, processing and presentation of tumor antigens and the presence, type 
and antigen specificity of TILs. Immunogenic tumor antigens can include oncoviral 
antigens, cancer germline antigens (CGA), and neo-antigens, which all have been 
reported to elicit T cell responses in cancer patients 199,200. Besides immunogenicity, 
immune evasive mechanisms can affect numbers and anti-tumor activity of T cells. 




(e.g., lack or down-regulated expression of chemo-attractants and/or adhesion mol-
ecules), antigen recognition (e.g., lack or down-regulated expression of molecules 
involved in antigen processing and/or presentation), and/or function of CD8 T cells 
(e.g., presence of immune-suppressor cells, altered expression of immune or meta-
bolic checkpoints, and/or activation of oncogenic pathways) 31,201. 
Current reports on prognostic and predictive value of TILs in BC subtypes to a cer-
tain extent refer to some of the above mechanisms yet remain inconclusive and 
sometimes even contradictory 58,191.  In the current study, we have comprehensively 
assessed immunogenicity as well as T cell evasive mechanisms in BC subtypes with 
respect to characteristics of TILs and the tumor micro-environment (TME). To this 
end, we applied a series of omics analysis tools on large publicly available datasets 
and demonstrated that BC molecular subtypes significantly differ with respect to 
extent of immunogenicity and occurrence of dominant T cell evasive mechanisms, 
qualities that go beyond the mere presence of TILs. These novel findings may aid fu-
ture immune therapy trial design and rationalize implementation of differential com-
bination-immune therapies for BC subtypes.
 
3.2 Results
TIL signature is prognostic for basal-like, her2 and luminal B, but not luminal 
A nor normal-like BC
We have built a 109-gene (120-probe) signature (additional file 1) that captures stro-
mal TIL abundance, according to the guideline method from Salgado and colleagues 
56 (Figure 1A-E). Since TILs can be highly heterogeneous with respect to their com-
position of T cells and other immune cells, we performed immune fluorescence stain-
ing followed by digital image analysis and observed strong correlations between 
the TIL score and numbers of CD8 T cells (r=0.82, p<0.0001) as well as CD4 T 
cells (r=0.74, p<0.0001), but not macrophages (r=-0.031, p=0.9) (Supplementary 
figure S2). We further assessed this signature using the omics tools miXCR 202 and 
CIBERSORT 203. The first tool, which enumerates the sequence reads of T cell re-
ceptor alpha and beta chains (TCRα and β) from RNAseq data (Cohort B), revealed 
that the number of TCR-Vβ reads in a specimen strongly correlated with the TIL 
score (computed as average of all 109 genes per sample) of the same specimen 
(r=0.91, p<0.0001, Figure 1D). The second tool, a deconvolution algorithm that ex-
tracts relative proportions of 22 major immune cell populations from microarray data 
(Cohort A), revealed that proportions of CD8 T cells, activated memory CD4 T cells, 




TIL scores, whereas proportions of resting DC, Neutrophils, Monocytes, M0 Mac-
rophages, and activated mast cells negatively correlated with these scores (Sup-
plementary figure S3). Collectively, these findings point out that TIL-high samples 
(median of 35% sTIL) are enriched for activated lymphocytes and reflect frequencies 
of αβ T cells, and that TIL low samples (median of 5% sTIL) are enriched for immune 
suppressor cells.
Figure 1. TIL signature captures frequencies of CD8 T cells. A, Hierarchical clustering of normal-
ized gene expression values of a TIL signature in BC samples from Cohort A, discovery set (344 LNN 
and treatment-naive BC patients). Sample assignment is as follows: dark-grey marks high-TIL samples 
(containing median of 35% sTILs), light-grey marks low-TIL samples (median of 5% sTIL), based on hier-
archical clustering. Figures B and C show high-magnification close-ups (100X) of H&E stained slides of 
BC with high and low TIL abundance, respectively. TILs are identified as small round dark stained cells 
amidst the cancerous tissue. D, Scatterplot with pearson correlation (blue line) between TIL score and 
number of total TCR-Vβ reads extracted from RNAseq data (n= 347, cohort B). E, Scatterplot with cor-
relation (blue line) between the percentage of stromal TILs assessed using HE-stainings and TIL score 
(n=60, cohort A).
Next, we assessed the prognostic value of our TIL signature and observed an asso-
ciation with distant MFS in the discovery set of 344 LNN primary BC (p=0.009, Sup-
plementary figure S4A). To validate our findings, we performed similar analyses in 
a dataset of 523 primary operable, LNN BC and verified a significant association be-
tween TIL abundance and MFS (p=0.016, Supplementary figure S4B). Following 
this validation, and to increase statistical power for subgroup analysis, we combined 
the discovery and validation sets of samples (Cohort A, n=867) and explored the 
association between TIL scores and MFS in the different molecular BC subtypes (for 
hormone receptor status per molecular subtypes see supplementary figure S1). 
Basal-like and her2 had equally high TIL scores followed by normal-like BC, whereas 
luminal-A and B subtypes showed the lowest TIL scores (p<0.0001, Figure 2A). TIL 
scores had prognostic value in univariate cox regression only in basal-like (log-rank 
p=0.002), her2 (log-rank p= 0.04) and luminal-B (log-rank p=0.02) subtypes, but not 
in luminal-A or normal-like subtypes (Figure 3 B-F). Notably, TIL scores remained 




multivariable cox regression including tumor size and age (Table 1A). To investigate 
the biological basis of differential prognostic values of TILs we subsequently evalu-
ated TIL and TME characteristics among BC subtypes.
Figure 2. TIL abundance provides differential prognostic values across BC subtype. A, Violin plots 
with TIL-scores per BC subtype (molecular subtypes according to AIMS). Statistical differences were 
calculated using Kruskal-Wallis test among subtypes, and Wilcoxon rank sum test for pairwise compari-
son relative to basal-like BC; p-values are indicated as: ‘***’<0.001, ‘**’<0.01, ‘*’<0.05. Figures B-F show 
Kaplan Meier curves of Cohort A (867 LNN BC patients) by subtype with high versus low TIL scores. 
TIL-status was assigned as explained in legend to figure 1.
Numbers of clonally expanded T cells were high in basal-like but low in lumi-
nal-A BC
Since T cell clonality can be indicative for tumor reactivity of TILs 204, we assessed 
TCR-Vβ reads in TIL-high samples of different BC subtypes. Basal-like BC showed 
the highest number of different T cell clones (i.e., highest TCR repertoire diversity, 
average number=109), which was significantly higher than her2 (61), normal-like 
(50), luminal-A (39) and luminal-B BC (35) (Figure 3A). In agreement, basal-like BC 
showed the highest read-counts of the 10 most abundant clones per sample (Figure 
3B). Highly expanded clones (HEC), which were defined as clones with read-counts 
> 10% of total clone reads, were present in basal-like, her2 and luminal-B tumors. 
Interestingly, luminal-B but not A tumors harbored HECs (Figure 3C), whereas both 
tumor types had equally low TCR repertoire diversity. Notably, in all subtypes, indi-




Expression of neo-antigens and CGAs is highest in basal-like and her2 BC, yet 
independent of TIL abundance
To evaluate antigenicity we assessed expression of two categories of recognized 
targets for CD8 T cells, namely neo-antigens and CGAs. We used non-synonymous 
mutations (cohort B, see Materials and Methods) and evaluated CGA expression 
(cohort B, average expression of 239 CGAs per sample). Neo-antigen expression 
was significantly higher in basal-like BC (average number=21.5) compared to lumi-
nal-A (7) and B (17), and normal-like BC (15), but not compared to her2 BC (17.5) 
(p<0.001, Figure 3D). CGA expression was again significantly higher in basal-like 
BC compared to luminal-A and B and normal-like BC, but not her2 BC (p<0.002, 
Figure 3F). When correlating antigen expression to TIL-scores, we observed a slight 
positive correlation with neo-antigen expression (r=0.2, p=0.0017, Figure 3E). Inter-
estingly, CGA expression was inversely correlated to TIL-score (r=-0.21, p=0.00082, 
Figure 3G).
Genes related to T cell evasion are differentially expressed among BC sub-
types
Besides parameters of immunogenicity, we evaluated differential expression of genes 
related to three main categories of T cell evasion (influx and migration of T cells; an-
tigen processing and presentation; and function of T cells, Figure 4). With respect to 
influx and migration of T cells, basal-like BC showed the highest expression of che-
mo-attractants, which was significantly lower in other subtypes. Normal-like tumors 
showed the highest expression of T cell adhesion genes (followed by basal-like BC) 
and those related to cancer associated fibroblasts and extracellular matrix products 
(Figure 4A). With respect to antigen recognition by T cells, basal-like BC showed 
the highest expression of antigen processing and presentation (APP) genes, which 
was significantly lower in all other subtypes (Figure 4B). Type-I IFN gene products, 
which are recognized for their effects towards antigen priming 205, were equally high 
in basal-like, her2 and luminal-B, but expressed to significantly lower levels in lu-
minal-A and normal-like subtypes. With respect to T cell function, we evaluated the 
expression of co-stimulatory ligands and receptors (for co-stimulatory and inhibitory 
receptors which are expressed by T cells, we compared TIL high samples only), 
immune mediators of the TME, components of oncogenic pathways (see additional 
file 2 for details), and frequencies of immune (-suppressor) cells (based on CIBER-
SORT deconvolution). Again, basal-like tumors showed the highest expression of 
co-inhibitory receptors and ligands as well as co- stimulatory receptors and ligands. 




other subtypes, while expression of corresponding ligands was equally high in her2, 
but not other subtypes. Expression levels of mediators such as IL10, IDO-1, VEGF, 
components of adenosine and glycolysis pathways, which can all limit T cell function, 
were also highest in basal like BC, and significantly decreased in all other subtypes. 
Interestingly, while M0 macrophages were significantly enriched in basal-like BC, 
frequencies of regulatory T cells, monocytes and M2 macrophages were highest in 
luminal-B tumors (Figure 4C).
Figure 3. T cell clonality and antigen expression is highest in basal, her2 and luminal B subtypes. 
A, Boxplots with total number of unique TCR-Vβ reads per BC subtype. B, Stacked bar charts with the 
average read numbers of the 10 most abundant T cell clones (according to TCR-Vβ reads) per BC sub-
type. C, Bar charts with proportions of BC subtypes with highly expanded clones (HEC, >10% of all clone 
reads), expanded clones (EC, 5-10% of all clone reads) and other clones (<5% of all clone reads). D and 
E show total number of neo-antigens per BC subtype and its correlation with TIL abundance on a log scale 
(Pearson, r=0.2, p=0.0017, CI: 0.95). F and G show CGA expression (average of all CGAs per sample) 
per BC subtype and its correlation with TIL abundance on a log scale (Pearson, r=-0.21, p=0.00082, CI: 
0.95). Statistical differences were calculated using Kruskal-Wallis test among subtypes, and Wilcoxon 





When interrelating TIL score with above-mentioned gene sets in a subtype-indepen-
dent manner, we observed that this score correlated significantly with co-inhibitory/
stimulatory receptors and NFKB-pathway (r>0.7), which may be expected because 
all of these gene-sets can be expressed by T cells. Weaker correlations (r<0.6) were 
observed between the TIL score and antigen processing, and IFN signatures. For 
other gene-sets we observed weak (adenosine, immune mediators), no (glycolysis) 
or even inverse correlations (M0, WNT-pathway) with TIL-scores (see supplementa-
ry Figure S5 for details, interactions between gene-sets and TIL score and subtypes 
are indicated in Figure 4).
Figure 4. Immune and metabolic checkpoints as well as M0 macrophages are enriched in bas-
al-like, T cell adhesion molecules are enriched in normal-like, and regulatory T cells and M2 are 
enriched in luminal-A and B BC. Violin plots with expression levels per BC suptype of Cohort A. A, 
Chemo-attractants, adhesion molecules, Cancer associated fibroblast and their products; B. Antigen pro-
cessing and presentation, Type-II interferon genes; C. co-stimulatory receptors (TIL-high samples only), 
co-stimmulatory ligands, co-inhibitory receptors (TIL-high samples only), co-inhibitory ligands, immune 
mediators , adenosine pathway as well as immune cell frequencies from CIBERSORT deconvolution, as 
well as glycolysis- and beta-oxidation pathway (for details of gene-sets see additional file 2). Statistical 
differences were calculated using Kruskal-Wallis test among subtypes, and Wilcoxon rank sum test for 
pairwise comparison relative to basal-like BC; p-values are indicated as: ‘***’ <0.001, ‘**’<0.01, ‘*’<0.05. * 





Finally, we performed Cox regression analyses with MFS to determine the prognos-
tic value of the above gene-sets in uni- and multivariable settings (Tables 1A and 
1B; for prognostic value of single genes, see additional file 3). Besides TIL scores, 
we found significant associations with MFS (Hazard Ratio (HR) <1, p<0.05) for the 
following gene sets: Type-II IFN in BC (not differentiated per subtype), as well as 
her2 and luminal-B subtypes; co-inhibitory/stimulatory receptors and ligands in BC, 
as well as basal-like, her2 and luminal-B subtypes; antigen processing and presen-
tation in BC, as well as basal-like and luminal-B subtypes; and NFKB pathway in BC 
as well as basal-like subtype. In addition, activated memory T cells were significantly 
associated with MFS in BC and basal-like, in the multivariable analysis. Interestingly, 
we found significant inverse associations with MFS (HR>1, p<0.05) for M2 macro-
phages in BC; M0 macrophages in normal-like subtype; glycolysis and adenosine 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CD8-positive TILs in BC are generally associated with a favorable clinical course, yet 
response to immune therapies is overall low, does not go hand-in-hand with CD8 TIL 
abundance, and differs significantly across subtypes. Tumor-immune interactions 
are not well understood and are expected to contribute to lack of response to im-
mune therapies. In this study, we have addressed immunogenicity and T cell evasive 
mechanisms according to multiple parameters in a cohort of 867 LNN, untreated 
primary BC and a cohort of 437 primary BC with WGS data. To this end, we have 
built a 109-gene TIL signature that preserves differential prognostic value of TILs 
across molecular BC subtypes. We found that T cell clonality, antigenicity, frequency 
of immune suppressor cells as well as expression of genes related to influx/migra-
tion, antigen recognition or suppression of T cells provide significant determinants of 
individual subtypes and may explain the differential prognostic value of TILs.
The TIL signature used in this study was based on quantitative pathological assess-
ment of TILs on HE-stained BC 206. TILs generally comprise a variety of different im-
mune cell population including subsets with pro-and anti-tumor activity 207. Neverthe-
less, we found that this signature correlated very well with numbers of CD8 T cells, 
frequencies of activated lymphocytes (cell types associated with good prognosis) 
and inversely correlated with immune suppressor cells (cells associated with poor 
prognosis), suggesting that it may be used to assess T cell abundance when tissues 
are not available. Moreover, we observed a near perfect correlation between TIL 
score and TCR-Vβ read counts, suggesting that TCR-Vβ read counts also act as a 
surrogate for TIL abundance in silico (correlations between TIL density and either TIL 
score (r=0.82, p<0.0001) or TCR-Vβ read counts (r=0.76, p<0.0001) are compara-
ble). TIL scores were high in basal-like, her2 and normal-like BC. T cell abundance, 
however, was not a prerequisite for prognosis since TIL scores were only associated 
with MFS in basal-like, her2 (univariate analysis only) and Luminal-B subtypes, but 
not in luminal-A, nor normal-like subtypes. 
Assessment of immunogenicity and T cell evasive mechanisms per subtype re-
vealed that basal-like, her2 and normal-like tumors harbor the highest TCR reper-
toire diversity. TCR clonality, however, was highest in basal-like, her2 and luminal-B 
tumors, which suggests that a tumor-specific T cell response has taken place in the 
latter three BC subtypes and to lesser extent in luminal-A and normal-like tumors 
(despite high TIL score and TCR diversity in normal-like tumors). Even though T 
cell clonality assessment based on bulk RNAseq analyses has several limitations 
208 and should be interpreted with caution, it is interesting that a recent study by 




active capacity of TILs is highly variable in different cancers and that a proportion 
of TILs represents true bystander T cells 209, which may be the case for the majority 
of TILs in normal-like tumors. In line with T cell clonality, basal-like BC showed the 
highest expression of neo-antigens and CGAs, followed by her2 and luminal-B tu-
mors. These observations suggest that a certain level of antigen expression, which 
is considered a pre-requisite for an anti-tumor T cell response, and the presence 
of clonally expanded T cells, which is a consequence of T cell responses, may at 
least in part explain the prognostic value of TILs in basal-like, her2 and luminal-B 
subtypes. Nevertheless, when correlating neo-antigens to TIL scores or T cell clon-
ality we only observed a weak correlation, which did not hold true upon subtype 
stratification (except for luminal-B tumors, which may be due to overrepresentation 
of APOBEC-driven neo-antigens that are considered more immunogenic than other 
neo-epitopes 149), suggesting that, at least in other subtypes, predicted antigens are 
not truly immunogenic. Undoubtedly, the landscape of antigens goes beyond CGAs 
and classical neo-antigens (derived from non-synonymous mutations), to which end 
we have evaluated correlations between TILs and alternative mutations (i.e., frame-
shifts, indels, drivers, passengers) which did not improve correlations with TILs (data 
not shown). The lack of strong correlations between antigenicity and TILs may hint to 
the occurrence of immune editing or other immune evasive mechanisms. 
When evaluating genes related to T cell evasion, we observed that expression of 
chemo-attractants was highest in basal-like BC followed by her2. T cell adhesion 
molecules on the other hand, were highest in normal-like BC, which may explain the 
relatively high TIL scores as adhesion molecules may enhance T cell retention 210 
irrespective of antigen-specificity. Vice versa, low expression levels of adhesion mol-
ecules in luminal-B tumors may explain the low TIL score measured for this subtype. 
Looking into antigen recognition by T cells, we demonstrated that APP was lowest 
in luminal-A, -B and normal-like tumors. Nevertheless, we observed a significant 
association of the APP gene set with survival in luminal-B tumors, suggesting that 
APP is functional in at least a subset of these patients. Loss of function mutations in 
APP genes have been reported to result in immune resistance towards CI therapies 
in melanoma 159,160. Along this line, it is noteworthy that we found 1 or more mutations 
in APP genes in 10% of basal-like patients, a fraction of patients that is 2 to 5-fold 
higher compared to the other BC subtypes (see Supplementary figure S6). Type I 
interferons, such as IFNα and IFNβ, produced either by tumor cells or dendritic cells, 
are critical for priming of CD8 T cells and significantly impact natural as well as ther-
apy-induced immune control of tumors 205. Moreover, it has been shown that mice 
lacking type I IFNs spontaneously develop breast tumors 211. Expression of type-I 
IFN genes were equally high in basal-like, her2 and luminal-B tumors and showed 




value of TILs in these subtypes. Interestingly, we observed that the abundance of 
memory CD4 T cells was associated with better survival in BC and basal-like BC, 
which has recently also been shown by others 212. We found that this T cell subset 
was enriched in TIL-high samples of basal, her-2 and luminal-B tumors, which sug-
gest that not only quantity but also quality of the T cell infiltrate matters.  
Lastly, when analyzing modes of T cell suppression, we observed that gene-sets 
for both co-inhibitory/stimulatory receptors showed significant interaction with TIL 
scores and were associated with survival in basal, her2 and luminal-B tumors (as 
were TIL scores), which is in agreement with the concept that immune checkpoints 
become expressed following a tumor-specific T cell response, since these mole-
cules are often expressed in response to IFNγ 213. M0 and M2 macrophages, cell 
types which have been associated with various modes of immune suppression and 
tumor progression in BC 214, were inversely correlated with MFS in BC, which is in 
agreement with findings by Ali and colleagues 67. Immune inhibitory mediators, which 
can be secreted by MDSC or tumor cells, were also expressed at the highest level 
in basal-like BC, and as a gene set demonstrated a high HR in this subtype. Next to 
suppressor cells, also oncogenic and metabolic pathways have been linked to T cell 
evasion. In example, increased glycolysis has been linked to decreased trafficking 
and cytotoxicity of T cells in other malignancies 215. Intrestingly, it has been observed 
that glycolysis signaling can induce MDSC development, via induction of G-CSF and 
GM-CFS in BC 216. In line, we observed co-expression of MDSC and glycolysis sig-
natures as well as inverse correlations with TIL scores. Notably, these observations 
could be caused by a single common process or due to the co-existence of multiple 
biological processes, indicating that mechanistic conclusions should be drawn with 
caution. Components of oncogenic pathways, such as WNT and adenosine, were 
expressed at the highest level in normal-like and basal-like BC, respectively, and re-
markably WNT genes were associated with poor prognosis in BC, basal like BC, and 
luminal-A BC. WNT has been linked to decreased recruitment of T cells in melanoma 
and it has been shown recently, that WNT signaling can modulate PD-L1 expression 
in cancer stem cells of BC 217, suggesting that WNT plays a role in multiple modes 
of T cell evasion.
In Figure 5, outcomes of parameters of TILs and tumor micro-environment are sum-
marized per BC subtype, and pointing to the differential qualities of TILs and occur-
rence of T cell evasive mechanisms, which may represent important biomarkers 
when monitoring patient responses to immune therapies. Based on our multi-pa-
rameter analyses in relation to subtypes, TIL scores and prognosis, we argue that in 
particular T cell clonality, expression of co-inhibitory molecules, type-I IFN, APP and 




In agreement, recent results of the TONIC trial showed that T cell clonality correlat-
ed with response to pembrolizumab, when combined with chemotherapy, in TNBC 
218. A recent trial in which trastuzumab-resistant Her2+ patients were treated with 
pembrolizumab showed clinical benefit for patients whose tumors were positive for 
PD-L1 219, a marker that is frequently up-regulated following anti-tumor T cell re-
sponses 213. Moreover, the Impassion130 trial, in which 902 TNBC patients were 
treated with atezolizumab with/without nab-paclitaxel, revealed that only patients 
Figure 5. Summary of in silico analyses of TILs and tumor micro-environment per BC subtype. 
Heat maps with normalized expression of immune gene-sets (high expression in red, low expression in 
blue). Cohort A was used to calculate average gene expression per BC subtype, except for highly ex-
panded clones (HEC), neo-antigens and CGAs for which Cohort B was used (for individual analyses, see 
Figures 1-4). Abbreviations.: NFKB, nuclear factor kappa-light-chain-enhancer of activated B cells; PW, 




with PD-L1-positive immune infiltrate showed clinical benefit 220. In line with our 
study, these findings argue that the mere presence of CD8 TILs is not sufficient to 
accurately chart immune responses, and that markers that reflect the quality of TILs 
should be included to monitor future trials. In extension to this concept, our findings 
on the quality of TILs and the immune micro-environment, in particular with regard 
to subtype specific differences in metabolic and oncogenic pathways as well as re-
cruitment of different types of suppressor cells may aid the design and translational 
testing of subtype-specific (combination-) therapies (see examples below). Of note, 
despite good concordance between subtyping methods and highly similar results 
for immune-gene analysis in histological and corresponding molecular subtypes 
(supplementary Figure S7), the here presented subtypes do not fully resemble the 
subtypes used in daily clinical practice. Moreover, we have used gene expression 
data at bulk level to interrogate BC subtypes for their immunogenicity and immune 
evasive mechanisms, which subsequently need to be validated in future studies. 
Based on this study, in basal-like BC, there is a strong rationale for testing combina-
tions of checkpoints with inhibitors of oncogenic pathways, MDSC or immune medi-
ators. Possible combinations include drugs targeting VEGF or adenosine receptors, 
which are FDA approved for other implications and showed synergistic effects with 
CI in pre-clinical models and early clinical studies, including TNBC 221. Furthermore, 
several WNT-PW inhibitors, which are currently in clinical trials  (including studies in 
breast cancer) or drugs depleting MDSC 222, which are mainly in preclinical develop-
ment, may increase efficacies of ICI in basal-like BC.  
In Her2 BC, even though generally being immunogenic, there may be insufficient 
numbers of tumor reactive T cell clones when compared to basal-like BC (despite 
equally high TIL scores). Given the high antigenicity and relatively low frequencies 
of immune-suppressor cells, adoptive T cell therapy with TCR-engineered T cells 
may be considered to treat this tumor type. In fact, chimeric antigen receptor (CAR) 
T cells targeting her2 effectively kill BC in mouse models, however, in patient studies 
severe on-target toxicities have been observed 223. Nevertheless, based on our data, 
CGAs and neo-antigens are frequently expressed in her2 BC and may represent 
safe targets for AT. 
In luminal-B BC, at least a subset of tumors may very well be immunogenic and may 
benefit from immune therapies. In fact, TIL scores and expression of APP genes, 
although being low, were prognostic, and TIL scores correlated to the presence of 
neo-antigens in this tumor type. The generally low frequencies of T cells, which may 
be due to low expression of chemo-attractants and adhesion molecules, argues in 
favor of treatments that enhance accumulation of T cells (chemotherapy or epigene-




In addition, Luminal-B tumors were enriched for M2 macrophages and regulatory T 
cells, which also represent targets in this tumor type for combinatorial treatments 225.
In Luminal-A BC and normal-like BC, we observed the least signs of immunogenicity 
and immune evasion implying that these tumor types are unlikely to respond to im-
mune therapies. A recent case study, on the other hand, reported complete regres-
sion of a luminal-A patient following treatment with tumor reactive TILs 198. Important-
ly, however, this patient had an exceptionally high number of mutations, indicating 
that these results may not be generally translatable to other luminal-A tumors. 
Finally, normal-like BC, demonstrated enrichment for CAF and their products as well 
as T cell adhesion molecules, which is suggestive for enhanced T cell retention and 
may explain relatively high TIL scores. This, together with the low expression of an-
tigens and markers for ongoing immune responses, suggest that normal-like tumors 
are also unlikely to respond to immune therapies, but may benefit from therapies that 
target CAFs and/or their products.
3.4 Conclusion
Our data suggest that not frequencies of TILs per se, but rather qualities of TILs (i.e. 
T cell clonality, T cell subset distribution, APP, expression of type-I IFNs and immune 
checkpoints); and immune micro-environments (in particular oncogenic- and meta-
bolic pathways as well as types and frequencies of suppressor cells) discriminate 
BC subtypes. Furthermore, our data suggest that evaluation of multiple immune pa-
rameters using NGS data enables charting of immunogenicity and immune evasive 
mechanisms, and provide a guide to select combinatorial approaches which may 
enhance the efficacy of future immune therapy trials.
 
3.5 Materials and Methods
Gene expression datasets
Cohort A: Gene expression data (HG-U133-A array) of lymph node–negative (LNN) 
BC patients (who did not receive any adjuvant systemic treatment) were retrieved 




GSE11121 (n=200) 228, GSE2990 (n=125) 229 and GSE7390 (n=198) 230. To assess 
the prognostic value of TILs in different BC subtypes, GSE2034 and GSE5327 con-
stituted a discovery cohort (n=344), whereas GSE11121, GSE2990 and GSE7390 
(n=523) constituted a validation cohort. Raw cel files of all GSE-entries were down-
loaded and data were normalized using fRMA 231 and corrected for batch effects 
using ComBat 232. Subsequently, to retain significant power, the combined cohort of 
867 LNN primary BC was used for in depth analyses of TILs and the TME within BC 
subtypes as described below. 
Cohort B (BASIS): Secondly, a unique dataset was retrieved from primary  BC cas-
es  with both WGS (n=560) and in depth RNA sequencing data (n=347) and which is 
accessible through EGAS00001001178 149,233. From cases for which both WGS and 
RNAseq were available (n=266), the data were used for predicting neo-antigens and 
from the cases which had just RNAseq data (n=347), the data were used for analysis 
of T cell clonality.
Ethics statement
This study has been approved by the medical ethical committee at Erasmus MC 
(MEC.02.953), and was performed according the Declaration of Helsinki and the 
“Code for Proper Secondary Use of Human Tissue in The Netherlands” (FMWV, 
version 2002, update 2011) of the Federation of Medical Scientific Societies in The 
Netherlands (http://www.federa.org/), the latter aligning with authorized use of coded 
spare tissue for research.
TIL signature
To assess TIL abundance, we used a previously published 206, but slightly modified 
TIL signature. In brief, the signature was built based on assessment of the proportion 
of TIL nuclei of total nuclei (including TIL, tumor and resident stromal cells) for mul-
tiple representative areas of H&E stained slides from 96 familial BC samples by an 
experienced pathologist (CD). Gene-expression data (Affymetrix HG-U133_plus_2.0 
array) from GEO54219 234 of corresponding samples was split in two groups based 
on TIL abundance (high and low TIL count, median split), and tested for differen-
tial gene expression, which resulted in a 152 probe signature that highly correlates 
with TIL percentages in  the specimen (r=0.74, p-value < 0.001)206. From the 152 




109 genes, see additional file 1) were found to overlap with the HG-U133_A array 
(Cohort A), and were used to classify samples based on TIL abundance according to 
average linkage hierarchical clustering (correlation as distance metric) in this study. 
TIL high samples contained a median stromal TIL count of 35% whereas TIL-low 
samples had a median stromal TIL count of 5%. The limitation to 120 probes in this 
study did not affect TIL scores calculated from either RNA–seq or microarray data 
(correlations between original and modified signatures, r=1, p-value < 0.001).
Assessment of prognostic value of the TIL signature
The prognostic value of this signature according to distant metastasis-free survival 
(MFS) was tested with cohort A. In the discovery set, mean age at time of surgery 
was 53 years (standard deviation (SD), 12); 221 patients (64%) were ER-positive; 
120 patients were assigned to the TIL-high cluster (35%); 198 patients were pre-
menopausal (58%). T1 tumors (<=2 cm) were present in 168 patients (49%), T2 
tumors (>2–5 cm) in 163 patients (47%), T3/4 tumors (>5 cm) in 12 patients (3%), 
and unknown tumor stage in 1 patient. With respect to disease spread, 226 patients 
(66%) did not develop metastasis at a distant organ during follow-up (median fol-
low-up time of patients still alive was 101 mo; range, 61–171 mo). In the validation 
set, 404 patients were ER-positive (77%); 166 patients were assigned to the TIL-
high cluster (32%); and 387 patients (74%) did not have metastasis at a distant or-
gan during follow-up (median follow-up time of 124 months). An overview of clinical 
characteristics per molecular subtype is given in supplementary table 1. To reduce 
inter-experimental variation and minimize biases, both datasets were combined by 
batch mean centering 235, and subsequently used for hierarchical clustering to divide 
samples in high and low TIL abundance groups using the 120 probe sets of the TIL 
signature.
Subtyping breast cancer
Samples were assigned to subtypes according to BC intrinsic molecular subtypes 
(AIMS) as described by Paquet and colleagues 196 using the Bioconductor R pack-
age genefu 236. AIMS subtyping is considered the most stable subtyping based on 
expression data, as it is not affected by normalization or subtype frequencies in the 
cohort. It is noteworthy that AIMS subtyping has good concordance with PAM50 
molecular subtypes as well as histological subtypes and preserves prognosis of sub-
types 196. For a breakdown of hormone receptor status (ER, PR and Her2) per mo-




mune-gene sets in AIMS and histological subtypes see supplementary Figure S7.
Immunogenomic tools
T cell clonality (TCR repertoire diversity and convergence): T cell receptor-β 
chain (TRB) reads were extracted from RNA-seq (Cohort B, n=347) using the miX-
CR 202 algorithm, available at https://github.com/milaboratory/mixcr. In brief, the soft-
ware aligns the sequencing reads to reference V,D,J and C genes of the T-cell re-
ceptors (TCR), assembles the clonotypes and exports the clones per sample.  Since 
total TCR-Vβ reads significantly differed among BC subtypes, we used only TIL-high 
samples to compare TCR clonality.
Antigen/mutational load: DNAseq and RNAseq data (Cohort B, n=266) were 
used to determine load of neo-antigens and expression of cancer germline antigens 
(CGAs). Neo-antigens and epitopes were predicted as described in 149. Briefly, 17-
mers of amino acids containing an amino acid arisen through a non-synonymous mu-
tation at the center position were run through the online prediction server Net-MHC 
to predict EC50 values of all possible 9-mer peptides for HLA-class I molecules, and 
a peptide with a predicted EC50<50 nM was considered a possible neo-epitope. List 
of CGAs (n=239) was extracted from CT database (http://www.cta.lncc.br/), and their 
expression levels were determined relative to expression of all CGAs per patient.
Frequencies of immune cell populations: Microarray samples (Cohort A, n=867) 
were used for deconvolution of 22 immune cell populations (LM22) using CIBER-
SORT (203, https://cibersort.stanford.edu/). Prognostic values of immune cell popula-
tions towards MFS were assessed by Cox regression analysis following classifica-
tion into “high” and “low” groups, split by the median frequency.
Genes related to T cell evasion
Genes related to T cell evasion (n=850, see additional file 2) were selected from 
reports from others  34,35,160 as well as the Laboratory of Tumor immunology (PI: RD), 
Dept Medical Oncology, Erasmus MC (reviewed in 31,201). These genes represent 
different T cell evasive mechanisms, and can be divided into 3 main categories, 
namely genes related to: (1) influx and migration of T cells; (2) antigen processing 




categories (see additional file 2). Notably, 4/24 genes of the category immune check-
points were also present in the TIL signature. Differential gene expression analysis 
was performed for Cohort A in R using Limma 237. Genes that were differentially 
expressed among BC subtypes (Benjamini-Hochberg adjusted P-value <0.05) were 
grouped according to above-mentioned categories of T cell evasion.  Gene-sets with 
a clear direction (>90% up- or downregulated) were displayed using violin plots and 
heat maps. Heat maps were made using average expression of gene-sets per BC 
subtype. For comparison of gene-sets expressed by T cells, only TIL high samples 
were considered.
Statistical analysis 
Differential gene expression was tested using Kruskal-Wallis tests, and compari-
sons of gene expression levels versus basal-like BC were performed with Wilcoxon 
tests. Distant MFS was used as endpoint for prognosis and log-rank tests were 
used to test survivor functions. Cox regression analyses were performed to assess 
prognostic value of gene-sets (and single genes, see additional file 3) in a uni- as 
well as multivariable (stratified for tumor size and age) model for the entire cohort A 
and per individual subtype. An interaction test was performed for all covariates with 
molecular subtypes. Kaplan-Meier curves were used to plot survival probabilities of 
subtypes/patients selected based on gene expression. Stata v13 (StataCorp, Col-
lege Station, Texas, USA) was used to calculate differences and 2-sided p-values of 
< 0.05 were considered statistically significant. 





Figure S1. Hormone receptor status per BC molecular subtype. Stacked bar-plots show percentage or 
estrogen receptor (ER, left), progesterone receptor (PR, middle) and human-epidermal growth factor re-
ceptor (Her2, right) as assessed by immune histochemistry of the same patients, per BC subtype.
Figure S2. Scatterplots with pearson correlations (blue lines) between immune cell densities (cells/μm2) 
of A, CD8 T cells (identified as CD3+ CD8+); B, CD4 T cells (CD3+ CD8-) or C, macrophages (CD68+) 




Figure S3. Correlations between proportions of immune cell populations and TIL score in BC. Scatter 
plots with correlations (blue lines) between fractions of immune cell subsets and TIL-scores (only dis-




Figure S4. Prognostic value of TIL signature in LNN BC. A, Kaplan-Meier curves of estimated MFS for pa-
tients in Cohort A, discovery set (n=344, p=0.009). B, Kaplan-Meier curves of estimated MFS for patients 
in Cohort A, validation set (n=523, p=0.016).
Figure S5. Correlation matrix of gene-sets related to T cell evasion. Numbers represent correlation co-




Figure S6. Mutations or down-regulated expression of antigen processing and presentation genes in 
BC subtypes. A, Expression of genes related to APP. B, Proportion of BC patients with one or more mu-
tations in APP genes. Statistical differences were calculated using Kruskal-Wallis test among subtypes, 
and Wilcoxon rank sum test for pairwise comparison relative to basal-like BC; p-values are indicated as: 
‘***’<0.001, ‘**’<0.01, ‘*’<0.05. 
Figure S7. Sets of immune genes show similar levels of expression between molecular (AIMS) and 
histological subtypes (hormone receptors). A. selected gene-sets associated with immune response. B. 




Clinical Basal Her2 LumA LumB Normal
characteristics samples % samples % samples % samples % samples %
ER- 138 71.5 50 44.6 9 4 6 4.2 30 15.6
ER+ 23 11.9 33 29.5 166 73.1 101 70.6 105 54.7
n.d.(ER) 9 4.7 29 25.9 52 22.9 36 25.2 57 29.7
PR- 73 37.8 31 27.7 14 6.2 19 13.3 16 8.3
PR+ 16 8.3 15 13.4 74 32 34 23.8 42 21.9
n.d.(PR) 104 53.9 66 58.9 139 61.2 90 62.9 134 69.8
HER2- 71 36.8 18 16.1 63 27.8 32 22.4 33 17.2
HER2+ 1 0.5 22 19.6 0 0 4 2.8 3 1.6
n.d.(HER2) 121 62.7 72 64.3 164 72.2 107 74.8 156 81.3
T1 75 38.9 53 47.3 137 60.4 68 47.6 123 64.1
T2 116 60.1 56 50 82 36.1 75 52.4 65 33.9
T3 1 0.5 2 1.8 6 2.6 0 0 3 1.6
T4 1 0.5 1 0.9 1 0.4 0 0 1 0.5
G1* 1 0.5 3 2.7 27 11.9 3 2.1 15 7.8
G2* 9 4.7 10 8.9 32 14.1 23 16.1 16 8.3
G3* 64 33.2 27 24.1 8 3.5 18 12.6 9 4.7
G1# 3 1.6 2 1.8 35 15.4 6 4.2 45 23.4
G2# 28 14.5 28 25 82 36.1 54 37.8 75 39.1
G3# 68 35.2 102 91.1 12 5.3 24 16.8 8 4.2
Supplementary Table 1. Clinical characteristics of Cohort A per molecular subtype.
Abbreviations: ER: estrogen receptor; Her2; human epidermal growth-factor receptor 2; G: clinical 
grade; n.d.: not determined; PR: progesterone receptor; T: tumor size.
*clinical grade determined by Bloom-Richardson grading
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Adoptive transfer of TCR-engineered T cells is a potent therapy, able to induce clin-
ical responses in different human malignancies. Nevertheless, treatment toxicities 
may occur and, in particular for solid tumors, responses may be variable and often 
not durable. To address these challenges, it is imperative to carefully select target 
antigens and to immunologically interrogate the corresponding tumors when design-
ing optimal T cell therapies. Here, we review recent advances, covering both om-
ics- and laboratory tools that can enable the selection of optimal T cell epitopes and 
TCRs as well as the identification of dominant immune evasive mechanisms within 
tumor tissues. Furthermore, we discuss how these techniques may aid in a rational 
design of effective combinatorial adoptive T cell therapies.
Highlights
1) Novel algorithms that surpass the mere binding to HLA- I and integrate multiple 
immune parameters, including immunopeptidomes and TCR:peptide binding modes, 
are expected to accelerate the selection of valid target epitopes and corresponding 
TCRs for AT.
2) Immunophenotyping combining laboratory and in silico tools is required to assess 
and understand local T cell immunity, and where the tumor evades T cell control, and 
provide a rationale for combination AT.
3) In silico tools guide qualitative assessment T cell infiltration, antigen recognition 
and T cell function.
4) Advanced imaging techniques enable simultaneous acquisition on the spatial dis-





5.1 Successes and Challenges of TCR-engineered T Cells
Adoptive T cell therapy (AT) refers to the infusion of tumor-reactive T cells that can 
recognize and kill malignant cells. AT requires T cells to be isolated from a patient, 
expanded and activated ex vivo, and re-infused back into the patient. This therapy, 
when using T cells with introduced genes encoding T cell receptors (TCRs), has al-
ready resulted in impressive clinical responses in a number of human malignancies, 
such as metastatic synovial sarcoma, melanoma and multiple myeloma 190,389. Be-
sides clear objective responses (OR: 55-80%), these studies demonstrated durable 
complete regressions (CR: 2-20%) 31. 
While TCRs targeting the tumor antigen new york esophageal squamous cell carci-
noma-1 (NY-ESO-1) have been proven successful without treatment toxicities, tar-
geting melanoma antigen recognized by T cells 1 (MART-1) 284 or melanoma-asso-
ciated antigen 3 (MAGE-A3) 30,375 has led to severe toxicities caused by recognition 
of cognate antigens (see Glossary) or highly similar antigens outside tumor tissues. 
In addition to side-effects, multiple clinical trials demonstrated variable therapeutic 
efficacy (OR and CR as low as 12% and 0%, respectively), which in case of solid 
tumors has been largely attributed to the suppressive nature of the tumor micro-en-
vironment (TME) 31. 
In recent years, next-generation sequencing (NGS) techniques as well as those to 
detect and localize markers in tissues, have developed tremendously fast and yield-
ed an overflow of valuable immune-genomic and proteomic data. These data, when 
analyzed with the appropriate and latest tools, enable researchers to address the 
above challenges of AT with TCR-engineered T cells. Here, we provide an overview 
of novel omics and laboratory tools, and discuss how to implement these tools to 
select truly tumor-specific epitopes and TCRs, as well as to detect tissue profiles 
and identify immune evasive mechanisms. Furthermore, we present a new strat-
egy to define patient subgroups according to target epitopes, TCRs and immune 
evasive mechanisms to maximally sensitize the TME for T cells, while minimizing 
treatment-related toxicities and therapy resistance.
5.2 Avenues to Selecting Target Epitopes and TCRs
Target Antigens for AT: Not a Blind Choice
T cell target antigens should ideally be selected according to the following features: 
the ability to elicit a cytotoxic CD8 T cell (CTL) response; a high and homoge-
neous expression in the tumor but not in healthy tissues; and preferably shared by 




ing those listed above), and despite being generally immunogenic and shared by 
many patients, only a small fraction of these antigens is truly tumor-selective (absent 
in healthy tissue) 286. Among various tumor antigens, one can broadly distinguish 
between antigens that are shared and non-shared among patients. Shared anti-
gens, such as those that are over-expressed, as well as differentiation antigens, are 
also expressed in healthy tissues, and targeting such antigens can result in severe 
on-target toxicities 287. Cancer Germline Antigens (CGAs), even though generally 
considered to be tumor-selective, CGAs are not in all cases completely absent from 
healthy tissues 288. In fact, only 60 of the 276 known CGAs are transcriptionally silent 
in normal human, non-germline tissues 152. Non-shared neo-antigens, as well as a 
number of shared CGAs and oncoviral antigens, are tumor-selective (see for details 
287). In this review, we focus on these last three classes of antigens as targets for 
TCR-engineered T cells. An overview of reported immune as well as clinical features 
of these classes of human antigens is given in Table 1.
Workflow for Target Antigen and Epitope Selection 
Recent technical advances in NGS and ‘omics’ tools have facilitated selections of 
target antigens. In a first step, DNA and RNA sequencing of tumors and healthy tis-
sues can enable the identification as well as expression analysis of antigens. Identi-
fication of potential neo-antigens requires comparison of DNA changes identified in 
tumor- with matched normal samples. Identification of oncoviral antigens requires 
mapping of DNA against the gene information broker for viruses (GIB-V) database 
289. Besides the use of NGS data, CGA expression in tumors and healthy tissues can 
also be analyzed by the use of gene expression platforms or public databases, such 
as the Cancer Genome Atlas (TCGA) 279 or the Expression Atlas 290. In extension 
to NGS and gene expression data, we recommend verifying antigen expression in 
tumors as well as absence in healthy tissues by quantitative PCRs and, whenever 
possible, via immunohistochemistry.
In a second step, candidate epitopes (from the selected target antigens) can be 
predicted in silico. In general, human leukocyte antigen (HLA) class I epitopes are 
8-11 amino acids long, and their immunogenicity depends on the level of expression 
as well as efficiency of processing and presentation, while the latter events in turn, 
can depend on: proteasomal cleavage; post-proteasomal trimming; binding affinity 
for transport associated proteins (TAP, required for epitope loading onto HLA); and 
binding affinity for HLA 291. In silico prediction requires the integration of various com-
putational tasks and the proposed workflow for selecting tumor-specific epitopes is 




at the moment, there are 22 different algorithms for HLA-typing which can be used 
for mapping sequencing reads against the ImMunoGeneTics (IMGT-HLA) database 
(https://omictools.com/hla-typing-category). For instance, HLA-miner, POLYSOLV-
ER, seq2HLA, and OptiType can be used for NGS-data, whole exome sequencing 
(WES) data as well as RNA sequencing (RNAseq) data. Next, the prediction of an-
tigen-processing and presentation is covered by numerous algorithms that assess 
different parameters of epitopes, including the occurrence of proteasomal cleavage 
sites (NetChop), the binding affinity for HLA-I (MSIntrinsicMC, NetMHC, SYFPEITHI, 
RANKPEP), and the binding affinity for TCR (Repitope). Finally, prediction of HLA 
affinities of identical and highly similar epitopes (e.g. using Expitope 2.0 292 and the 
SysteMHC Atlas 293) should be performed to limit risks of toxicities294.
Most of the above epitope selection algorithms capture binding to common HLA 
alleles quite accurately, yet have been less trained for antigen processing and pre-
sentation of native epitopes (see Table 2 for a comprehensive list of algorithms). In 
fact, the presence and immunogenicity of only a minority of predicted epitopes has 
been validated in vivo, which may, in addition to suboptimal epitope prediction or lack 
of high-throughput methods to detect low frequencies of epitope-specific T cells, be 
due to immune editing295. Of note, currently available tools cannot yet predict faith-
fully HLA-II-restricted epitopes due to the lack of training data.
Recently, a number of NGS-based pipelines for in silico prediction of neo-epitopes 
with different degrees of functionality have been developed 296. These include newer 
and potentially improved algorithms that incorporate additional parameters, such 
as: RNA expression levels297; TCR-peptide interaction298,299; and the modelling of 
immunological fitness of tumor antigens300. In addition to these in silico develop-
ments, progress in the fields of immunopeptidomics and TCR structure might further 
enhance predictions of peptide presentation and recognition. For example, mass 
spectrometry (MS)-based methods can nowadays deliver and identify sequences 
of a significant part of the entire proteome within a few days, which allows high 
throughput measurements of natively presented peptides297,301,302. Upon immune 
precipitation of HLA molecules and subsequent sequencing of eluted peptides, one 
can measure the immunopeptidome of tumors or antigen presenting cells (APCs)303. 
At present, the large number of cells required for MS methods still presents a limita-
tion. Moreover, studies of TCR structure, currently covering 345 crystal structures of 
human TCRαβ’s (www.rcsb.org/pdb) and increasing numbers of molecular-dynam-
ics simulations, have increased our knowledge of TCR-peptide binding modes and 
common structural motifs304,305. These binding modes and structural motifs may aid 
the future creation of homology models of newly sequenced TCRs and the prediction 




Workflow for TCR Selection
Once epitopes have been selected, the next step is to obtain corresponding TCRs. 
One can obtain TCRs either from autologous patients’ tumor infiltrating lymphocytes 
(TILs) or from naïve T cells derived from HLA-matched healthy donor peripheral 
blood mononuclear cells (PBMCs). The latter represents a viable source of T cells 
that have been observed to recognize more predicted epitopes compared to autol-
ogous TILs 307, possibly as a result of a less skewed TCR repertoire. Various in vitro 
protocols to acquire epitope-specific T cells have been established and general-
ly include several rounds of stimulation with autologous- or artificial APCs that are 
loaded with an epitope or transfected with a minigene (harboring epitopes), followed 
by fluorescence-activated cell sorting of T cells binding to epitope-MHC multimers 31. 
Recent advances in single cell RNA sequencing (scRNA-seq) as well as numerous 
algorithms for read-mapping (scTCRseq, TRAPeS) have enabled the identification 
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across all cancers) 365 
<0.003% shared in 
more than 5% patients 
336
HPV: 5% of all 
cancers 364
HTLV: 10% of HTL 366 
EBV: 95% of NPC 
(1.5% of all cancers) 
367
NY-ESO-1: 80% of SCC; 20-35% of 
NSCLC; 42% of BC 368 
MAGE-A3: 33% of NSCLC 369
MAGE-C2: 40% of met melanoma, 
20% of HNSCC; 30% of ER- BC; 
15% of Bladder cancer 370













TAnti-tumor response Neo-antigen T cells: 
case reports in mela-
noma and cholangio-
carcinoma 372 
HPV TILs: 30% OR in 
cervical cancer 373
EBV T cells: 63% OR 
in NPC 355 
NY-ESO-1 TCR T cells: 55% OR 
in met melanoma; 61% in SS; 80% 
in MM 190 
MAGE-A3 TCR T cells: 55% OR in 
melanoma 374
Treatment toxicity none None 373 NY-ESO-1: none 283
MAGE-A3: neurologic and cardiac 
toxicities 30,285  
Immune editing recurrence of 
mutation-negative 
tumors 375 
occurrence of escape 
mutations 376
recurrence of antigen-negative 
tumors 283
Table 1. Three Classes of T Cell Target Antigens: Immune and Clinical Features. Abbreviations: 
BC: breast cancer; EBV: Epstein-Barr Virus; HPV: Human Papilloma Virus; HTLV: Human T-Lymphotropic 
Virus; met: metastasized; MM: multiple myeloma; NPC: nasopharyngeal carcinoma; NSCLC: non-small 




of reproductive TCRαβ sequences, i.e., TCR sequences harboring complete V(D)J 
rearrangements, from single cells 308. Such methods are not only fast but can also 
inform on the correct pairing of TCRα and β chains. The capture of single cells and 
reading depths of 500k, which are required for full recovery of reproductive TCR 
sequences 309, however, may pose a financial burden. Subsequently to the acqui-
sition of TCR sequences, these are cloned and inserted into donor T cells. For this 
purpose, retro- and lentiviral vectors have already proven useful and safe tools with 
clinical precedence 310. 
In addition, TALEN or CRISPR-mediated gene editing may enable the replace-
ment of endogenous TCRs by transgenes 311. Such gene replacement can result 
in increased and more homogenous surface expression of TCR transgenes, while 
reducing mispairing with endogenous TCRs, thereby inducing a potent anti-tumor 
Figure 1. Selection of Target Epitopes and Corresponding T Cell Receptors. A. Workflow for epi-
tope selection: Identification of immunogenic epitopes (yellow peptides) is accomplished using either 
in silico tools (left path, example tools in italic) for the prediction of HLA alleles, antigen processing and 
presentation, and cross-reactivity, or laboratory tools, such as mass spectrometry for the collection and 
analysis of HLA-presented epitopes (right path). B. Workflow for the identification and testing of TCRs: 
includes enrichment of epitope-specific T cells using epitope-loaded APCs, followed by FACSort of TCR 
positive cells (with epitope-MHC-multimers) and subsequent sequencing of TCR genes. TCR genes can 
then be cloned into donor T cells and tested for their specificity, affinity (e.g. alanine scan) and recogni-
tion of endogenously processed and presented epitopes. Abbreviations: APC: antigen presenting cell, 
FACS: fluorescence-activated cell sorting, IFNγ: interferon gamma, GRZM: granzyme B, MHC-I: major 
histocompatibility complex-I, PBMC: peripheral blood mononuclear cells, TCR: T cell receptor, TRA: T cell 




Tool parameter(s) tested output source
NetChop 376 occurrence of c-terminal proteasomal cleav-age sites










-epitopes and anchor residues for common 
HLA alleles
ranked binding score http://www.syfpeithi.de/
RANKPEP 
378
- binding affinity for common HLA alleles 
-immune dominance (based on: peptide pro-
cessing, MHC stability and TCR binding)
-proteasomal cleavage sites
-masking of sequence variability regions (i.e., 
mutational hotspots in virus)






-MHC affinity of wild type and mutant epitopes
-Filtering based on affinity score





-Identification of mutated peptides
-Similarity to wild type peptides
-Binding affinities for common HLAs
-Filtering based on RNA expression
Ranked neo-epiopes with 
annotation, HLA-affinity 






- expression of neoantigens








-binding affinities of mutant and wild type 
epitopes for common HLA alleles





-gene expression of antigen in healthy tissue
-binding affinity for common HLA alleles 
-homology with self-epitopes
expression levels in 
healthy tissues and 
nanomolar affinity score 






-gene expression of antigen
-MS peptide elution from HLA alleles
-proteasomal cleavage sites
native presentation score currently not publicly or 
commercially available
Reptiope 298
-binding affinity for TCR based on amino acid 
contact profiles 




Table 2. Examples of Algorithms for Epitope Prediction. Abbreviations: HLA: Human leukocyte anti-




response and limiting potential off-target toxicities 312,313 without the need of viral vec-
tors 314. Finally, once the T cell product has been generated, we recommend a series 
of in vitro assays to assess efficacy and safety of the TCR T cell product prior to clin-
ical implementation. Such assays 287, can include: an amino acid scan to determine 
the TCR’s recognition motif; screens against allo-alleles and peptides eluted from 
the corresponding HLA allele to exclude cross-reactivity; titrations of cognate pep-
tide to determine the TCR T cell’s avidity; and T cell assays using tumor and healthy 
cells to validate recognition of endogenously presented peptides. The workflow for 
selecting epitope-specific TCRs is illustrated in Figure 1B.
5.3 Patient Stratification According to Local T Cell Immunity
Antagonizing Immune Suppressive TMEs: Not a Blind Choice Either
Solid tumors are not only heterogeneous with respect to antigen expression but also 
with respect to numbers, location and activation state of intra-tumoral T cells. Local T 
cell immunity is determined by multiple parameters and may provide predictive value 
of responsiveness to AT, that goes beyond markers of mere tumor antigenicity or 
mutational load. Parameters capturing local T cell immunity may include: influx and 
migration of T cells; antigen recognition by T cells; and/or function of T cells. These 
three categories may be defined by unique immune markers, and recent advances 
in in silico- and microscopy tools are expected to significantly boost immunopheno-
typing of tumors, and enable rational selections for co-treatments aiming to enhance 
efficacy of AT. 
Influx and Migration of T Cells: The presence and intra-tumoral location of CD8 
T cells can be considered as measurement of general immunogenicity of tumors as 
well as the ability of these cells to infiltrate the tumor. Vice versa, absence of CD8 
T cells may either indicate a lack of immunogenicity or the presence of barriers that 
could hinder the infiltration of (adoptively transferred) T cells. Important for the re-
cruitment of T cells are inflammatory chemokines, and while many chemokines may 
be present in the TME, the interferon (IFN)-inducible and epigenetically regulated 
C-X-C motif chemokines CXCL9 and CXCL10, which recruit CXCR3-positive CD8 
T cells 317, may be of particular relevance to the AT setting. Notably, in a mouse 
model for spontaneous melanoma, basic leucine zipper ATF-like transcription fac-
tor 3 (BATF3)-dependent dendritic cells (DCs) were a major source of CXCL9 and 
CXCL10 and BATF3 gene knock-out abolished recruitment of adoptively transferred 




venules (HEV), was found to correlate with numbers of TILs in human breast cancer 
318, and these HEVs, which are equipped with adhesion molecules such as vascu-
lar cell adhesion molecule 1 (VCAM1), P-Selectin and E-Selectin 319, contribute to 
trans-endothelial migration of T cells into tumors. Of note, tumor endothelial cells 
with down-regulated surface expression of adhesion molecules, mediated for in-
stance via vascular endothelial growth factor (VEGF), can inhibit trans-endothelial 
migration of T cells, whereas up-regulated surface expression of FAS ligand (FASL) 
on tumor endothelial cells (via anti-inflammatory mediators, such as interleukin (IL)-
10) can lead to killing of FAS-expressing effector T cells ex vivo 320. Moreover, in-
filtration and migration of T cells can be compromised by the collagen-density and 
structure of the extracellular matrix (ECM), which can provide a physical barrier to 
T cells, as evidenced by real time imaging of human T cells in lung and ovarian 
cancer 321. ECM-mediated T cell exclusion has been attributed, at least in part, to 
an increased activity of cancer-associated fibroblasts (CAFs) and their production 
of cytokines, such as transforming growth factor beta (TGFβ) and IL6, since  levels 
of which inversely correlated to the presence of TILs in urothelial cancer patients 
treated with anti-PDL1 antibody 277 and a mouse model of colon cancer, respectively.
Antigen Recognition by T Cells: A crucial factor contributing to efficient tumor 
clearance by CD8 T cells is antigen expression, processing and presentation. Down-
regulation or loss of function (LOF) mutations in components of the antigen presen-
tation pathway have been shown to be a major resistance mechanism to immune 
therapies, including AT in various human malignancie. LOF mutations frequently 
occur in (but are not limited to) B2M, TAP1 or HLA genes. In fact, a CRISPR-Cas 9 
genome-wide screen in human melanoma cells pointed to antigen presentation and 
IFNγ-signaling being critical for effector functions of TCR-engineered T cells in vitro 
324. Interestingly, another study also demonstrated that LOF mutations in the novel 
marker APLNR (a G-protein coupled apelin receptor involved in JAK/STAT signaling) 
were present in human melanoma, which were refractory to immune therapies, and 
that knocking out the APLNR gene in mice resulted in enhanced melanoma tumor 
growth following AT with TCR-engineered T cells 325. Besides gene mutations, epi-
genetic alterations represent another cause of limited type-I and type-II IFN signaling 
and decreased tumor immunogenicity, a notion that is supported by the observation 
that ablation of the histone demethylase LSD1 in mouse melanoma resulted in en-
hanced IFN signaling and CD8 T cell infiltration, and that expression of LSD1 in var-
ious human malignancies is inversely correlated with presence of CD8 TILs 326. Yet 
another way to escape from antigen recognition by T cells is immune editing, where 




cell clones (for references, see Table 1).
Function of T Cells: The TME is often nutrient-deprived and hypoxic which can 
adversely modulate T cell development and function. For example, hypoxia and its 
downstream metabolites can reduce T cell proliferation and effector functions while 
increasing the expression of co-inhibitory receptors on T cells 327. Moreover, hypoxia 
can induce the accumulation of extracellular adenosine, which in turn can promote 
tumor cell proliferation and metastasis, and inhibit the function of immune effector 
cells, including CD8 T cells 328. Furthermore, increased glycolysis in tumor cells, as 
a result of the metabolic switch that can occur under hypoxic environments, or as 
a consequence of mutations in the phosphatase PTEN (pathway recognized for its 
contribution to cellular metabolism), has been found to limit the cytolytic capacities 
of T cells in vitro and to correlate with resistance to AT with TILs in melanoma and 
non-small cell lung cancer patients 215. In extension, immune-compromised mice 
transplanted with human melanoma cells that lack PTEN, and show enhanced PI3K/
AKT activation, revealed decreased T cell trafficking into tumors and resistance to 
CTL-induced apoptosis of tumor cells following AT with TCR engineered T cells 163. 
Also, increased WNT/β-catenin signaling adversely affects numbers of  TILs in mel-
anoma patients, with the underlying mechanism being studied in mouse models 
of spontaneous melanoma and attributed to decreased CCL4 expression by tumor 
cells, impaired DC recruitment, and T cell priming 329. From another angle, DCs ex-
pressing co-stimulatory ligands, such as, CD80, CD86, CD275 and CD252 can ac-
tivate CD8 T cells in tumors 330. In particular, a study with mouse breast cancer-de-
rived BATF3 DCs demonstrated that these cells efficiently cross-present antigen and 
provide co-stimulation when compared to conventional DC in vitro, and a study with 
a mouse melanoma model demonstrated that BATF3 DCs are crucial contributors 
to T cell priming and anti-tumor T cell activity in vivo 59.  Moreover, DCs producing 
pro-inflammatory mediators such as nitric oxide have been found to accumulate in 
murine melanoma following AT, cross-present tumor antigens and activate CD8 T 
cells via CD40-CD40L interactions 332. In fact, NOS2 and CD40LG gene expression 
correlated with survival in colorectal cancer patients 332. By contrast, tumor cells, 
CAFs, M2 macrophages or myeloid-derived suppressor cells (MDSCs), have been 
reported to downregulate co-stimulatory ligands and upregulate co-inhibitory ligands 
such as programmed death-ligand 1 (PDL1), herpesvirus entry mediator (HVEM), 
and CD155, often leading to T cell dysfunction, which has generally been assessed 
in ex vivo co-cultures of mentioned cell types and T cells, or in situ stainings of 
different human malignancies. In addition, soluble factors released by tumor cells 




(IDO1), can also inhibit T cell proliferation and activation or lead to T cell apoptosis, 
respectively (reviewed in 335).
Although there is still a vast amount of mechanistic understanding to be gained 
from immunophenotypes of various malignancies, particularly in terms of tissue-, tu-
mor- and species-specific contexts, there is a strong rationale for evaluating markers 
related to influx and migration, antigen recognition and function of T cells. Such an 
evaluation potentially enables the stratification of patients, and tailoring of single or 
combination AT. Timely examples of markers and tools to assess these three cate-
gories of local T cell immunity are illustrated in Figure 2.
Figure 2. Charting Immune Micro-Environments Using In Silico and Laboratory Tools. Schematic 
illustration of immune evasive mechanisms. Immunophenotyping of tumors should include the evalu-
ation of markers that predict: (1) influx and migration of T cells; (2) antigen recognition by T cells; and 
(3) the ability of T cells to sustain anti-tumor function. Abbreviations: α-SMA: alpha smooth muscle 
actin; APLNR: apelin receptor; BATF3 DC: basic leucine zipper ATF-Like transcription factor 3-positive 
dendritic cell; BTLA: B- and T lymphocyte attenuator; CAF: cancer associated fibroblast; CD: cluster of 
differentiation; CXCL9/10: chemokine (C-X-C motif) ligand 9/10, ECM: extracellular matrix; FASL: Fas 
ligand; FOXP3: forkhead box P3; GAL9: galectin-9, HEV: high endothelial venules; HVEM: herpesvirus 
entry mediator; ICAM-1: intercellular adhesion molecule 1; IDO-1: indoleamine 2,3-dioxygenase; LAG-
3: lymphocyte activation gene 3; M1: M1 macrophage; M2: M2 macrophage; MDSC: myeloid derived 
suppressor cells; MHC: major histocompatibility complex; OX40: tumor necrosis factor receptor super-
family, member 4, PD-1: programmed cell death protein 1; PD-L1: programmed cell death protein 1 li-
gand; PI3K: phosphatidylinositol-3-kinase; TAP: transport-associated protein; B2M: beta-2-microglobulin; 
TGFβ: transforming growth factor beta; TIL: tumor infiltrating lymphocytes; TIM-3: T-cell immunoglobulin 
and mucin-domain containing molecule-3; Treg: regulatory T cell; VCAM-1: vascular cell adhesion protein 




In Silico Tools for Immunophenotyping
Gene expression platforms and NGS technologies help determining the abundance 
of immune gene expression signatures, and, together with mutational and pathway 
analyses, are recommendable tools for a first screen of immune markers. Available 
databases and tools for functional annotation and pathway analyses include Con-
sensusPathDB 338, Reactome 339, DAVID 340 or IPA®. In addition, numerous in silico 
tools support dissection of the TME, such as those that characterize the cellular 
composition of immune cells or diversity of TCR sequences. An overview of in silico 
tools is given in Table 3. 
For instance, the presence of effector T cells and immune suppressor cells can be 
extracted from microarray expression- or RNA-seq data of bulk-tumor tissues using 
computational approaches that take into account sets of immune-specific marker 
genes or expression signatures 294. The most widely used approach is gene set 
enrichment analysis (GSEA). A limitation of GSEA-based methods is that they re-
port enrichment scores that do neither reflect nor translate into proportions of the 
analyzed cell types 294. Single sample GSEA (xCell) can address this shortcoming by 
calculating the abundance scores of immune cell types and calibrating these scores 
to resemble proportions 341. Unlike GSEA, deconvolution methods such as CIBER-
SORT 203, EPIC 342 or quanTIseq 343 convert gene expression data into relative frac-
tions of cell types according to cell type-specific expression profiles. Of note, quan-
TIseq combines deconvolution with image analyses of hematoxilin&eosin-stained 
samples thereby enabling “in silico multiplex staining” and prediction of immune cell 
densities 343. Next to immune cell composition, algorithms such as MiXCR, IMSeq, 
and RTCR assess T cell clonality, which may serve as a marker for antigen recogni-
tion by CD8 T cells and tumor responsiveness towards immune therapies (reviewed 
in 208).  
Tool performance input output
GSEAPreranked* GSEA of 28 immune gene sets
ranked list of gene 
expression
enrichment scores for individual gene 
sets
xCell 341 GSEA of single 
samples
genome wide expression, 
RNAseq
relative abundance of 64 immune- and 
ECM cell subsets
CIBERSORT 203
deconvolution genome wide expression relative abundance and absolute (beta 
version) numbers of 22 immune cell 
subsets
EPIC 342
deconvolution genome wide expression relative abundance and absolute (beta 





Laboratory Tools for Immunophenotyping
New imaging techniques can enable quantitative and spatial assessment of multiple 
immune markers related to AT, which may be particularly important for the evalua-
tion of the ability of CD8 T cells to infiltrate the tumor. Moreover, the activation state 
of TILs or cell to cell interactions can be assessed, which may provide insight into 
antigen recognition and T cell function. Multiplexed methods are either based on 
sequential imaging of single markers or simultaneous imaging of multiple markers. 
The former is time consuming, relies on image alignment, but does not require spe-
cialized equipment, whereas the latter has a higher degree of accuracy but does 
require sophisticated equipment and reagents (see Table 4). Sequential staining 
and imaging can be performed with IHC or IF protocols, such as cyclic immunofluo-
rescence (CycIF) 344 and MxIF 345, which both use chemical inactivation and remov-
al of fluorochromes, or multi-epitope ligand cartography (MELC), which uses pho-
to-bleaching and has been reported to image up to 100 markers in a single sample 
346. More recently developed methods enable simultaneous staining of a high num-
ber of markers followed by a single image acquisition. For instance, Vectra®-based 
multiplexed IF (up to 8 markers) relies on consecutive steps of staining and stripping 
of antibodies (leaving behind immobilized fluorophores) (reviewed in 347). Digital spa-
Tool performance input output
QuanTIseq 343 
deconvolution RNAseq relative abundance of 8 immune cell 






of genes and pathways
List of differentially 
expressed genes
Up- and down regulated genes and 




based on frequency 
and tumor purity









assignment of V(D)J 
genes and mapping on 
IMGT database
RNAseq (>150bp paired 
end reads)
V(D)J gene usage and number of CDR3 
reads
Table 3. Examples of  Omics Tools for Immunophenotyping. Abbreviations: ECM: extracellular ma-





tial profiling (DSP) enables quantitation of up to 800 markers targeting DNAs, RNAs 
and proteins simultaneously with a near single cell resolution (1-4 cells) 348. DSP 
uses the nCounter® barcoding technology (nucleic acids or antibodies labeled with 
an optical code) which relies on photo-cleavable tags that are digitally mapped back 
onto the tissue 348. Finally, imaging CyTOF/ mass cytometry (IMC) 349 can provide 
unprecedented and detailed views of tissue heterogeneity. IMC combines CyTOF, 
in which cellular targets are labeled with metal-tagged antibodies and quantified by 
time-of-flight mass spectrometry, with IHC and high-resolution tissue laser ablation 
to image dozens (50+) of proteins at sub-cellular resolution (<1µm) 349. Significant 
advantages of IMC in comparison to the above-mentioned methods are the absence 
of sample autofluorescence and a wide dynamic range, which makes this method 
highly versatile and quantitative 349. Highly multiplexed imaging methods, whatever 
the choice of method, generate complex multilevel data. Only with appropriate tools 





sequential staining with enzyme-labe-
led reagents , imaging of whole slide, 






sequential staining with fluores-
cently-labeled reagents, imaging of 






MxIF 345 sequential staining with fluorescent-ly-labeled reagents
conventional epifluores-
cence microscope 60
Axio Vision Mark 
& Find, ImageJ, 
other
MELC 346 
automated sequential staining with 
fluorescently-labeled reagents, imag-
ing of whole slide, photo bleaching of 
fluorochrome
fluorescence microscope 




for 3D images, 
other
Multiplex IF 347 
consecutive staining with fluorescent-
ly-labeled reagents, tyramide signal 
amplification (following each staining), 




System (Mantra, Vectra, 
Vectra Polaris)
8 InForm, TIBCO Spotfire, other
Imaging Mass 
Cytometry 349 
simultaneous staining with antibodies 
labeled with rare earth metal isotopes








simultaneous staining with nucleic 
acids or antibodies tagged with optical 
barcode
NanoString high-plex 
digital IHC microscope 800
nCounter Analysis 
system, other





and analysis software (summarized in Table 4) one can accurately and fully extract 
cellular phenotypes and spatial information such as cell-cell interaction networks, 
which together can be used to define clinically relevant features.
5.4 Adoptive T cell Therapy: Assessing TCRs and Designing 
Co-Treatments
Step-wise approaches for selecting safe target antigens and corresponding TCRs 
as well as co-treatments may further optimize AT. Once a target antigen, epitopes 
and corresponding TCRs have been identified and validated (as described above), 
patients can be screened for (single or combination) AT treatment. To this end, tumor 
biopsies (and patient’s blood for matched normal DNA to identify mutated epitopes) 
are used to assess: first, the status of target antigens and HLA alleles that present 
epitopes and second, the status of local CD8 T cell immunity. In a third step, infor-
mation of these two steps is used to design a combination AT treatment. These three 
steps can provide specific treatments for a patient (-subgroup) as illustrated in Fig-
ure 3 and examples based on the three immunophenotypic categories (with respect 
Figure 3. Patient Stratification According to TCRs and Co-Treatments. Proposed Workflow to stratify 
patients for combined AT (left). The color of patients represents the selected target antigen (shared: CGA 
or oncoviral antigens, patient specific: neo-antigens). Colored circles represent shortcomings in T cell 
immunity with respect to influx and migration (blue), antigen recognition (grey) and T cell function (green). 
Examples for co-treatments to counteract one or more (overlapping circles) immune evasive mechanisms 
are exemplified (right). Abbreviations: HLA: human leukocyte antigen; IFNs: interferons; TCR: T cell 




to local CD8 T cell immunity) are provided below. In case neo-antigens are targeted 
with AT, this treatment will be personalized regardless of the co-treatments.
Targeting oncoviral antigens or CGAs, however, warrants identification of groups of 
patients according to antigen and HLA expression. In general, antigens are mea-
sured by NGS or quantitative PCR, or in situ staining, when antibodies are available 
and staining protocols are operational. HLA alleles are mostly determined by genetic 
typing using PBMC-derived DNA. In the event no suitable antigen is expressed, a 
given patient may not be eligible for AT. 
When intra-tumoral T cells are absent, one potential explanation may be the lack 
of chemokines or adhesion molecules due to endothelial quiescence (see previous 
section for references). In such a case, infusion of very high numbers of CD8 T cells 
may already be sufficient to induce endothelial cell activation (via complement acti-
vation), release of chemokines and subsequent homing of adoptively transferred T 
cells 350. Other approaches for the normalization of the tumor vasculature include ad-
ministration of VEGF-inhibitors1, other tyrosine kinase inhibitors (TKI)* or epigenetic 
drugs*. The latter drugs, when exposed to ex vivo cultures of human ovarian cancer, 
have been reported  to induce IFN-response genes and again trigger the release of 
chemokines, and, when administered to NSG mice transplanted with human ovarian 
cancer, and co-treated with TILs, resulted in improved survival 317. In addition, com-
binations of TCR-engineered T cells with VEGF-inhibitors have resulted in increased 
numbers of intra-tumoral T cells in murine melanoma 351. When the lack of intra-tu-
moral T cells is attributed to an enhanced ECM barrier, combinations that include 
matrix degrading enzymes may be considered, exemplified by enhanced CAR T cell 
infiltration ex vivo, and clearance of human neuroblastoma in mouse model by CAR 
T cells that are engineered to express heperanase 352. 
When antigen expression or presentation is low, there is generally a rationale for 
combining AT with cytotoxic therapies (chemotherapy or radiation)* or epigene-
tic modifier treatment* (e.g.  histone de-acetlyating agents or DNA de-methylating 
agents) 353. Cytotoxic therapies increase immunogenic cell death and act synergis-
tically with AT 354, and certain epigenetic drugs such as azacytidine or entinonstad 
have been found to enhance the expression of some tumor antigens, such as CGAs 
183. If antigen expression is heterogeneous, or there is evidence for immune editing, 
one could opt to target multiple antigens simultaneously 355, each adhering to the 
criteria set out above. Lack of antigen recognition by T cells due to deficiencies in 
antigen processing and presentation downstream of genomic alterations, may imply 
that patients with such alterations are not eligible for AT. In case antigen processing 




one may opt for co-treatment with IFNs, TLR agonists1 (types: 2, 4, 7, 8 and 9), 
cytotoxic therapies, TKI, or epigenetic modifiers, as these have been reported to 
increase the expression of MHC- and/or co-stimulatory molecules in different human 
malignancies (reviewed in 356).
Finally, when T cells are dysfunctional due to the accumulation of immune suppres-
sor cells in tumor tissues, there may be a rationale for using drugs that could lead 
to macrophage depletion or re-polarization (CSF1R inhibitor and TNFα treatment, 
respectively) 225; and/or depletion or blocking the recruitment of regulatory T cells (via 
CD25 and CCR4*, respectively) 357. When immunophenotyping reveals that the acti-
vation state of intra-tumoral T cells is compromised, one may consider treatment with 
agonists for co-stimulatory receptors (CD137, OX40, ICOS). For instance, CD137 
antibodies combined with AT resulted in increased T cell infiltration and better kill-
ing of murine melanoma, which was evidenced by intravital microscopy 358. Alterna-
tive approaches include combinations with inhibitors of immune checkpoints (PD1*, 
CTLA4*), metabolic checkpoints (IDO1, adenosine1) or T cell inhibitory pathways 
(PI3K*, MAPK*, TGFβ*) 353.  Indeed, combinations of AT and PD1- and/or A2AR- in-
hibitors* resulted in increased CAR T cell efficacy in mouse models of breast cancer 
359. Along this line combinations with a BRAF-inhibitor1 have resulted in increased 
survival  and in vivo cytolytic activity of TCR engineered T cells in murine melanoma 
models 360. Yet another approach to overcome T cell dysfunction may be to execute 
ex vivo activation of T cells under hypoxic conditions, as hypoxic versus normoxic 
T cells demonstrate better proliferation, expression of granzyme-B and anti-tumor 
activity in murine melanoma models 361. (*FDA approval for various malignancie).
Besides combining AT with other therapies, one might also include additional 
gene-engineering to generate T cells that exhibit enhanced resistance to immune 
escape mechanisms. This approach has already been clinically exploited for CARs, 
which often harbor intracellular co-signaling domains, have knocked out checkpoint 
molecules or are engineered to produce chemokines or matrix degrading enzymes 
upon antigen engagement. For a more complete overview of gene-engineering to 
enable T cells to enhance numbers and activity in an immune tolerant environment, 
see 362.
It is important to note that many of these approaches and combination regimens still 
require validation, and the assessment of toxicities and potential off-target effects. 
Consequent, extensive and robust testing is required to investigate these approach-





Major advances in NGS- and laboratory technologies are paving the way towards 
improved AT in immuno-oncology. It is remarkable that personalized AT targeting of 
neo-antigens in combination with checkpoint inhibition has not only been feasible for 
certain malignancies (e.g. solid tumors), but has also resulted in a complete durable 
response in a chemo-refractory, metastatic breast cancer patient 198. These results 
indicate that patient-specific or patient group-specific AT might broaden the scope of 
responding tumor types, including those with low mutational burden, which are gen-
erally considered unresponsive to checkpoint blockade. Taken together, advanced 
immunophenotyping, which integrates NGS technologies, omics- and laboratory 
tools, is critically needed to provide a detailed characterization of T cell immunity in a 
patient’s tumor and antitumor response. This, together with the selection of safe and 
effective epitopes and corresponding TCRs might provide optimal combination AT 
treatments with safe and effective clinical profiles. Although many questions remain 
(see Outstanding Questions), it will be quite exciting to follow how these techno-
logical advances contribute to catalyzing the future of personalized or group-specific 
AT with TCR-engineered T cells.
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5.8 Glossary
allo-alleles: non self-allele which can be recognized by TCRs independent of the 
bound peptide
algorithm: a sequence of operations in computer science, such as calculating, data 
processing and automated reasoning.
avidity: binding strength based on multiple receptor target interactions (for instance, 
T cell avidity includes combination of TCR-peptide:MHC and CD8).




stricted to immune privileged tissues (germline) and tumors.
CAR T cells: T cells engineered to express a chimeric antigen receptor consisting of 
an extracellular antibody-domain, an intracellular TCR domain, and often a co-stim-
ulatory domain.
cognate T cell epitope: A defined stretch of amino acids (9-11 amino acids) that is 
derived from intracellular proteins which is specifically recognized by a TCR. After 
processing by the (immune-) proteasome, peptides are presented by MHC mole-
cules on the cell surface of target cells to the TCR on the cell surface of T cells. 
cross-reactivity: T cell reactivity against an epitope other than the cognate epitope 
(often highly similar to cognate epitope and recognized with lower TCR affinity).
complement activation: chain reaction of protein cleavage that can result in the 
activation of immune cells. 
differentiation antigens: class of tumor antigens that are expressed at different 
stages of tissue development or cell activation.
endothelial quiescence: inactive state of endothelial cells, generally with limited 
expression of chemokines, adhesion molecules, and co-stimulatory ligands, and 
consequently not favoring tissue entry of T cells.
immune suppressor cells: cells, including immune cells but also stromal cells, 
such as CAF, that can limit T cell function
immune checkpoints: receptors and ligands that upon ligation result in limiting ac-
tivation of immune cells (i.e., putting immune cells in check).
immune editing: interplay between tumors and immune system resulting in loss of 
antigen-positive tumor cells upon selective pressure by T cells.
immunopeptidome: collection of all presented peptides by MHC molecules of a 
target cell(s) or tissue.
immunophenotyping: assessment of immunogenicity and immune evasive mech-
anisms by omics and/or laboratory tools.
M2 macrophages: innate immune cells that normally are specialized in engulfing 
aberrant cells and presenting antigens, but due to polarization, which may be a con-
sequence of the tumor micro-environment, become immune suppressor cells. 




next-generation sequencing: high throughput sequencing method of nucleic acids.
whole-exome sequencing: sequencing of all protein-coding genes of the genome.
omics: collection of sciences and necessary tools that focus on the structure and 
function, and related aspects, of defined groups of molecules (genomics: DNA; tran-
scriptomics: RNA; proteomics: proteins; metabolomics: metabolites; immunomics: 
immune markers etc).
oncoviral antigens: class of tumor antigens which are derived from viral genes that 
had been integrated into the DNA of (pre-)malignant cells.
on-target toxicity: toxicity due to T cells targeting their cognate epitope outside 
tumor tissue.
off-target toxicity: toxicity due to cross-reactive T cells recognizing an epitope very 
similar to the cognate epitope outside tumor tissue.
read-mapping: locating of experimental sequences (called reads), through align-
ment with a set of reference sequences.
reading depths: number of sequences (called reads) that include a nucleotide of a 
reconstructed sequence, also referred to as coverage.
TALEN or CRISPR-mediated gene editing: technologies that enable targeted ge-
nome editing through different principles (TALEN (transcription activator-like effector 
nucleases) relies on modified restriction enzymes to cut out specific sequences from 
DNA; whereas CRISPR/Cas9 (clustered regularly interspaced short palindromic re-
peats) relies on guide RNA and a DNA endonuclease activity to remove specifc 
sequences from DNA).  
TCR repertoire: diversity and abundance of TCR genes (often represented by β 
chain) used as a measure of T cell clonality; the more skewed a TCR repertoire, the 
more clonal the T cell response has been.
time-of-flight mass spectrometry: method to determine an ion’s mass-to-charge 
ratio via acceleration in a known electric field, by time measurement. 
TLR-agonists: natural or synthetic molecules that ligate to and stimulate Toll-Like 
Receptors (TLR), the latter being evolutionary conserved receptors generally ex-
pressed on innate immune cells and taking part in the recognition of pathogen-asso-
ciated molecular patterns.




tumor selectivity: expression of tumor antigens by cancerous tissue but not healthy 
tissue (immune privileged tissues represent an exception in case of CGAs)
5.9 Outstanding Questions
1) What are the exact underlying biochemical rules that determine the immunoge-
nicity of tumor antigens? What kind of data is required in order to improve epitope 
prediction algorithms for HLA-I, and ultimately also for HLA-II? 
2) Are there categories of resistance to AT that are not captured by deviations in 
influx and migration-, antigen recognition and dysfunction of T cells? Are there sub-
groups of patients with certain genetic or environmental states (SNPs or composition 
of gut microbiota) that despite combination treatment do not respond to AT?
3) With respect to an effective anti-tumor response, is there a hierarchy of certain 
immune markers? And would this hierarchy of markers (when existing, this would 
greatly enhance our understanding of tumor immunity and facilitate charting immune 
evasion) hold true in a pan-cancer setting, or be it specific per tumor subtype or even 
patient?
4) Can acquired resistance or compensatory immune evasive mechanisms be fully 
prevented when targeting one category of T cell control? Should one opt to target 
multiple events within one or multiple categories, so for instance antagonize multiple 
types of suppressor cells instead of a single type of suppressor cell to limit renewed 
T cell evasion through compensatory mechanisms? 
5) Since tumor-immune interactions are heterogeneous, not only across different 
tumor types, and within tumor subtypes, but also across different metastatic lesions 
within the same patients, would it be necessary to take biopsies from multiple sites 





Orthotopic T-cell engineering via CRISPR
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The simultaneous removal of an endogenous T-cell receptor chain and 
the orthotopic placement of an exogenous receptor in human T cells 
via CRISPR gene editing prevents the mispairing between endogenous 
and transgenic receptors while preserving the cells’ function.
Modifying human T cells for therapeutic purposes involves the ex vivo modification 
of a patient’s T cells to make them express selected T-cell receptors (TCRs) specific 
for viral or tumour antigens, and the reinfusion of the modified cells back into the 
patient. The injected cells then mount an immune response to the specific patho-
gens or cancer cells31. Clinical trials for testing TCR-engineered T cells have shown 
promising results against various tumour types (in particular, melanoma, synovial 
sarcoma and multiple myeloma)282,283, with objective response rates of 55–80% and 
complete response rates of 2–20% (ref.31). Because T cells express endogenous 
TCR αβ-chains, typical approaches for inserting exogenous TCRs in T cells may 
result in unwanted TCR combinations. In particular, TCR chain mispairing can occur 
when therapeutic TCR α-chains dimerize with endogenous TCR β-chains (or when 
therapeutic β-chains dimerize with endogenous α-chains), leading to mispaired het-
erodimers411 with new (and often unknown) antigen specificities. Such TCR heterod-
imers may trigger autoimmune reactions or graft-versus-host disease412. Also, the 
introduced TCR chains can compete with endogenous chains for the limited pool 
of adapter CD3 molecules, which may result in reduced surface expression and 
function of the therapeutic TCR (ref. 413). Moreover, the expression of the therapeutic 
TCR is often placed under the control of viral promotors, with loss of physiological 
regulation of TCR dynamics (including internalization and degradation of the TCR 
chains on antigen exposure414), which can result in tonic signalling of the therapeutic 
TCR, in decreased specificity, and in accelerated differentiation and exhaustion of 
the TCR-engineered T cells. Furthermore, the use of viral vectors to generate clin-
ical T-cell products involves time-consuming production pipelines and high costs, 
and can cause the uncontrolled integration of the therapeutic TCR in the genome 
(with potential effects on the expression and function of other genes415). Reporting 
in Nature Biomedical Engineering, Dirk Busch and colleagues now show that the 
use of CRISPR- Cas9 gene editing to orthotopically insert a therapeutic TCR into 
the endogenous TCR α-chain (TRAC) locus of human T cells and the simultaneous 
deletion of the endogenous TCR β-chain locus (TRBC) abrogates the mispairing of 
TCR chains and preserves the physiological regulation of the inserted TCR (ref. 416).
To study the assembly of individual TCR chains, Busch and colleagues used non-vi-
ral and viral gene-delivery methods to insert a fully human cytomegalovirus (CM-




or via CRISPR–Cas9-mediated knock-in into the endogenous TRAC locus. The en-
gineered cells showed similar levels of cytokine production and peptide sensitivity 
regardless of the protocol used, raising the possibility that TCR mispairing still oc-
curs in T cells expressing the endogenous TCR β-chain. Subsequent experiments 
for the identification of heterodimers of the inserted and endogenous TCR chains 
(in which the human therapeutic constant region of the TCR was replaced with a 
murine counterpart) showed no evidence of endogenous TCR expression (or of mi-
spairing) when TRAC and TRBC were simultaneously targeted with CRISPR–Cas9 
in human T cells. Notably, similarly to unmodified T cells, on antigen stimulation the 
engineered T cells produced cytokines and dynamically regulated the expression of 
TCR transgenes. Hence, appropriately paired TCRs with physiological dynamics, 
and better safety and functionality than virally transduced non-edited T cells, can be 
generated by shutting down the expression of both endogenous TCR chains and by 
inserting the therapeutic TCR orthotopically into the TRAC locus.
There are alternative strategies that diminish receptor mispairing and that enhance 
surface expression of the therapeutic TCR: in particular, TCR murinization, cyste-
ine modification, the use of co-stimulatory domains417, and the elimination of the 
endogenous TCR loci via microRNAs418, zinc-finger nucleases419, transcription acti-
vator-like effector nucleases420 or CRISPR–Cas9. For instance, TRAC knockout via 
CRISPR–Cas9 and the viral introduction of template DNA encoding a CD19-specific 
chimeric antigen receptor into the same locus led to the regulation of the expression 
of the receptor by the endogenous TCR promoter (rather than by an exogenous 
viral promotor)14. Endowing an inserted TCR with an endogenous genetic regulatory 
domain led to the delaying of T-cell exhaustion and to enhanced performance of the 
engineered T cells for effective clearance of the target tumour in vivo311. Others per-
formed TRBC knockout with CRISPR–Cas9, and lentivirally introduced a therapeutic 
TCR targeting the tumour-associated antigen NY-ESO-1; in this context the knockout 
T cells also showed increased expression and functionality of the therapeutic TCR 
when compared with T cells with intact endogenous TCR chains421. It is also possible 
to simultaneously perform non-viral TRAC knockout and TRAC knock-in of the TCR 
αβ-chains with CRISPR–Cas9 to generate TCR-modified T cells that target tumours 
expressing NY-ESO-1 (ref.422). Electroporation has also been used to knockout both 
TCR loci and to knock-in the TCR αβ-chains in the TRAC locus. Because TCRα and 
TCRβ chains may be regulated differently, it would be worthwhile to test the surplus 
value of knocking in an engineered TCR into both the TRAC and TRBC loci.
Busch and co-authors do not report the percentage of TRBC-knockout T cells 
when simultaneously editing the TRAC and TRBC loci. Yet they did not detect TCR 




knockout efficiencies of 50–90% are possible311,421, it may be challenging to routinely 
achieve such high efficiencies in large-scale clinical settings without the need for ad-
ditional screening, sorting, and method optimization. In addition, the evidence of ho-
mology-independent integration of the edited TRBC locus provided by the authors, 
together with the idea that the detection of random integration on a whole-genome 
level has low sensitivity, suggests that the system can still be optimized. Therapeutic 
T-cell engineering up to ~400 million TRAC knock-in cells can be generated after 10 
days of in vitro expansion16; non-viral transfer of CRISPR–Cas9 and double-strand-
ed DNA template may thus also be feasible in the clinical setting422. 
Fig. 1 | T-cell engineering for the generation of therapeutic T cells. The insertion of therapeutic T-cell 
receptors (TCRs) into human T cells can be done via viral and non-viral techniques (including the use 
of CRISPR-Cas9 gene editing with electroporation). Each approach has favourable and unfavourable 
outcomes, with simultaneous non-viral knock-in of the TCR alpha chain locus (TRAC-KI) and non-viral 
knockout of the TCR beta-chain locus (TRBC-KO) having particular advantages (although they will re-
quire optimization steps before they can be clinically implemented).
A drawback of non-viral delivery is its typically low gene-transfer efficiency; yet pre-
vious studies have shown that electroporated T cells are mostly viable and can be 
easily sorted prior to expansion. Although some of the procedures (CRISPR–Cas9 
editing, cell sorting, and in vitro expansion of T cells) have been clinically applied, 
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cell manipulations may negatively affect cell viability and the sustained function of 
the engineered T cells. Studies of the long-term functionality of engineered T cells 
in preclinical models are limited because T-cell engineering methods have not been 
optimized for murine T cells, and new immune-competent models would need to be 
developed. Yet further insights may also come from clinical studies: for example, a 
phase-I trial (NCT03399448) in which virally delivered CRISPR–Cas9 is used for a 
triple knockout of the endogenous TRAC and TRBC loci and of the immune check-
point factor programmed cell death-1, as well as of TRAC knock-in of NY-ESO1 TCR 
αβ-chains, is expected to shed light on the in-patient performance of the edited T 
cells. The next step would be non-viral editing and orthotopic delivery of TCR genes 
in a clinical setting. The optimization of technologies for the manufacturing of such T 
cells under requirements for advanced therapeutic medicinal products423, the choice 
of safe antigen targets, and strategies to maximally sensitize tumours for T cells201 









Chapter 8. General discussion
The major aims of this thesis were trying to close the knowledge-gap regarding T 
cell evasive mechanisms in breast cancer (BC, Part 1) and to identify new target 
antigens for adoptive T cell therapy to treat triple negative BC (TNBC, Part 2). This 
final chapter briefly summarizes and discusses the main outcomes, and puts them 
in perspective of future pre-clinical as well as clinical studies.
8.1 Outcomes Part 1: Charting T cell evasion
- Aspects of CD8 T cell immunity, such as antigen processing and presen 
 tation, co-signaling, clonality and subset distribution, and not mere num 
 bers of CD8 T cells, determine patient survival of BC subtypes
- A gene classifier accurately assigns spatial immunophenotypes, is prog 
 nostic in TNBC, and various other cancers and predicts anti-PD1 re 
 sponse in metastatic TNBC
- Next to TNBC, also HER-2 and luminal-B subtypes show markers that  
 reflect anti-tumor T cell responses which suggest that at least a subset  
 of these BC subtypes can benefit from (combination) immune therapies
- Spatial immunophenotypes in TNBC are characterized by distinct T cell  
 evasive pathways that advocate immune therapy in combination with  
 drugs that provide phenotype-specific sensitization
Box 1. Major findings
Stratifying BC patients for immune therapies
As discussed in Chapter 2 and based on the outcome of studies in Chapter 3, it 
is concluded that BC subtypes are not equally immunogenic, which is reflected by 
differential antigen load as well as differential prognostic values of tumor infiltrating 
lymphocytes (TIL). Antigenicity (i.e., expression of antigens, such as cancer germ-
line antigens (CGAs) and neoantigens) and numbers of TILs are generally higher in 
the more aggressive ER-negative subtypes, especially in TNBC. Taken the differ-
ences in antigenicity into account, it is not surprising that initial ICI trials showed the 
best responses in ER- disease, whereas ER+ (luminal) BC is generally considered 
unresponsive to ICI. In contrast to other tumor types, antigenicity turns out not to be 
a predictor of ICI response in TNBC19–21. Interestingly, mutations in the DNA-dam-




neoantigens424 and release of pro-inflammatory cytokines425, however, were not pre-
dictive for ICI response in TNBC218. In fact, we showed in Chapter 3 and in Chapter 
4 that neoantigens, irrespective of their type, only weakly correlate with numbers of 
TILs, and that BRCA status is not associated with a CD8 T cell inflamed phenotype. 
Notably, using node-negative, not systemically treated BC we observed that not TIL 
frequency per se, but rather markers reflecting an anti-tumor CD8 T cell response 
significantly impact prognosis in BC subtypes. Such markers include: (1) T cell sub-
set distribution; (2) TCR clonality; (3) gene-expression of molecules that contribute 
to T cell-co inhibition and (4) antigen processing and presentation. Since the above 
markers are all measures of the effectiveness of an anti-tumor CD8 T cell response, 
we argue that these markers may serve well as predictive markers for ICI response 
in BC. In fact, TCR clonality has already been associated with anti-PD1 response in 
TNBC, and several studies have shown that PD-L1 expression (an immune check-
point ligand that shows up-regulated expression following IFNy exposure) is cor-
related with response to ICI in TNBC and other BC subtypes. Furthermore, expres-
sion of the above-mentioned markers indicates that next to TNBC, at least a subset 
of HER2 and luminal-B subtypes may very well be immunogenic and responsive to 
immune therapies. Along this line, recent studies have shown that PD-L1+ HER2 
subtypes as well as ER+ BC patients benefit from ICI: ORs in metastatic PD-L1+ 
HER2+ and PDL-1+ ER+ patients were 15% and 12%, respectively219,426. More trials 
are underway427, and it is exciting to see how this type of therapy will further develop 
for different BC subtypes.
In a pan-cancer setting, it has become more and more evident that next to numbers 
and activation status of TILs, also their spatial localization matters with respect to 
survival and therapy responsiveness27,244,246,249,251. With this in mind, we have stud-
ied the spatial immune contexture in relation to clinical outcome in treatment-naïve 
TNBC and anti-PD1-treated metastatic TNBC (Chapter 4). In these studies, we 
have identified 3 dominant spatial immunophenotypes (covering nearly 100% of all 
tested cases), namely: the excluded immunophenotype, which was characterized by 
tumor margin-restricted localization of CD8 T cells; the ignored immunophenotype, 
which was characterized by absence of CD8 T cells; and the inflamed immunophe-
notype, which was characterized by the presence of intra-tumoral CD8 T cells that 
are evenly distributed among tumor margin and center. These spatial immunophe-
notypes could be captured by a gene-classifier, and had differential prognostic value 
in TNBC (i.e., the inflamed phenotype had the best survival, the ignored phenotype 
had the worst survival). Moreover, this gene-classifier also had prognostic value in 
cervical cancer, head and neck cancer, kidney cancer, bladder cancer and melano-
ma. We observed that the inflamed phenotype was enriched in those cancer types 




enriched in those cancer types that generally respond poorly to ICI. Importantly, the 
gene-classifier predicted response to anti-PD1 treatment in mTNBC with a negative 
predictive value of 0.9. In comparison, in the same dataset, PD-L1 expressed by 
immune cells, a currently and routinely used marker, had a negative predictive value 
of 0.4. Furthermore, we observed that assignment of different metastatic lesions 
from anti-PD1-treated TNBC resulted in a lower frequency of inflamed phenotypes, 
which is in line with recent reports428,429. This, together with the observation that as-
signment of these immunophenotypes did not depend on lesion site, argues that our 
gene-classifier may represent a viable and simple alternative to whole tissue stain-
ings. In fact, the assignment of spatial phenotypes is based on the expression of 42 
genes, which may be easily determined via standard molecular-based techniques 
and developed into a diagnostic tool. Collectively, these findings indicate that spatial 
immunophenotypes may improve patient stratification for ICI treatment and should 
be validated in other cohorts to test its value for incorporation into clinical practice.
Charting immune evasive mechanisms in BC
Despite the high number of studies on the prognostic and predictive value of TILs, 
up to now little emphasis has been given to immune evasive mechanisms in BC. 
In general terms, tumors may evade T cell control by: limiting T cell influx (i.e., 
down-regulation of expression of chemo-attractants or T cell adhesion molecules); 
halting the antigen processing and presentation machinery (i.e., selection for loss of 
function mutation); and lastly, suppressing T cell function (i.e., recruitment of sup-
pressor cells, up-regulation of expression of co-inhibitory molecules and suppres-
sive cytokines). New technologies, such as next-generation sequencing (NGS) and 
multiplexed imaging enable charting and identification of T cell evasive mechanisms 
(reviewed in Chapter 5). Along this line, we have studied the differential occurrence 
of T cell evasive pathways among BC subtypes using omics tools in Chapter 3 and 
performed in-depth and integrated analysis of NGS and multiplexed images from pri-
mary TNBC in Chapter 4. These chapters pinpointed towards different T cell evasive 
strategies in BC subtypes, which are shortly discussed below, including possible 
consequences for treatment choices, and illustrated in Figure 1.
Multi-parameter omics analysis suggests that luminal-B BC is characterized by low 
numbers of TILs, which may be caused by decreased retention of T cells from the 
blood in line with our observation of low expression of T cell adhesion molecules. In 
this regard, luminal-B BC may benefit from therapies that facilitate T cell infiltration, 
such as the CDK4/6 inhibitors abemaciclib, ribiciclib, or palbociclib. These agents 




BC. Their mechanisms of action are considered to be modulation of the immune 
micro-environment via up-regulated expression of type-I IFN response genes, and 
antigen processing and presentation genes. Notably, these agents were shown to be 
able to reverse a gene program in BC cell lines, which is associated with CD8 T cell 
exclusion in melanoma251,430. These preclinical results are encouraging, and suggest 
that ER+ BC may be primed for ICI when pre-treated with CDK4/6 inhibitors. In fact, 
a combination of abemaciclib and pembrolizumab induced OR in 14% of unselected, 
metastatic HR+ HER2- BC patients430,431. Furthermore, in Luminal-B BC we have 
observed high frequencies of M2 macrophages and regulatory T cells which may 
represent additional targets for combination therapies. Besides potentially enhanc-
ing clinical benefit of ICIs, inhibition of M2 macrophage may also improve standard 
therapies for ER+ BC as preclinical models have revealed that M2 macrophages 
facilitate endocrine resistance in BC432. Nevertheless, M2 inhibition has not yet been 
assessed clinically in BC, a path that certainly warrants future testing.
Similarly, luminal-A BC is characterized by low numbers of TIL, and presence of M2 
macrophages and regulatory T cells but in contrast to luminal-B BC, also low antigen 
load. This together with lack of prognostic value of immune parameters imply that 
this type of BC is unlikely to respond to immune therapies. Nevertheless, suppressor 
cells may represent actionable targets for combination therapies. 
HER2+ BC showed high numbers of TILs yet relatively few signs of anti-tumor T cell 
reactivity (i.e., few expanded TCR clones, low expression of co-signaling genes, and 
low frequencies of immune-suppressor cells). This type of BC is standardly treated 
with HER2-blocking antibodies, such as trastuzumab, and their modes of action have 
at least in part been related to antibody-dependent cellular toxicity and reported to 
provide synergistic effects when combined with ICI in preclinical models16. Given the 
low numbers of tumor-specific CD8 T cells and a relatively high antigen load, we ar-
gue that HER2+ BC is amenable to adoptive T cell therapy targeting other antigens 
than HER2. Future studies may utilize the strategy we applied in Part 2, to identify 
safe and effective T cell targets in BC subtypes other than TNBC (see section 8.2).
When compared to other BC subtypes, TNBC showed the highest number of clon-
ally expanded TCRs and also the highest expression of genes that represent im-
mune-suppressive mediators, myeloid-derived suppressor cells and oncogenic and 
T cell evasive pathways. When zooming in on the 3 spatial immunophenotypes as 
introduced above, we have identified unique determinants and evasive pathways 
that would warrant immunophenotype-specific combination therapies to treat TNBC. 
In brief, the excluded phenotype, which was associated with resistance to anti-PD1, 
demonstrated: deposits of collagen-10 that likely provide a physical barrier to CD8 




favorable environment for T cells; and highest gene-expression of serine protease 
inhibitors (SPI) that may limit T cell-mediated killing of tumor cells. All T cell evasive 
paths that occurred in the excluded phenotype were inversely correlated to the pres-
ence of CD8 T cells and associated with the activation of TGFβ/VEGF pathways. 
We argue that antagonizing TGFβ/VEGF pathways may limit T cell exclusion. In this 
regard, several inhibitors of the TGFβ/VEGF pathways are in clinical developments 
but have not yet been tested in combination with ICI in BC. Also, SPI represent 
interesting drug-targets as some members of this protein family (i.e., SERPINB3, 
SERPINB4 and SERPINB9) have been related to ICI resistance in melanoma433,434, 
and certain SPI can inhibit granzymes and/or caspases and could thereby promote 
tumor survival276,433. Nevertheless, their exact role in T cell evasion remains elusive 
and requires further research. The ignored phenotype was also associated with re-
sistance to anti-PD1 and demonstrated either high density of immune-suppressive 
M2 macrophages, which have been reported to suppress CD8 T cells, or activation 
of WNT/PPARγ pathways, which was inversely correlated to numbers of CD8 T cells 
and CLEC9A+ dendritic cells (DC). These observations suggest that antagonizing 
M2 macrophages or WNT/PPARγ pathways may promote CD8 T cell infiltration into 
ignored tumors and thereby sensitize them for immune therapies. In fact, a combi-
nation of WNT inhibition and ICI is currently being assessed in clinical trials including 
TNBC, albeit not stratified for presence of CD8 T cells. Finally, the inflamed pheno-
type, which was associated with response to anti-PD1, demonstrated signs of necro-
sis and a high density of CLEC9A+ DC that may trigger recruitment of CD8 T cells 
into the tumor. Also, the inflamed phenotypes showed a high TCR clonality that was 
independent of the quantity of neo-antigens. Notably, this phenotype showed signs 
of adaptive T cell evasion, such as enhanced expression of T-cell co-inhibitory re-
ceptors, high densities of M2 macrophages, and decreased expression of MHC mol-
ecules by tumor cells. Although the inflamed phenotype is generally most responsive 
to ICI, inflamed tumors may benefit from drugs that inhibit M2 macrophages or drugs 
that enhance antigen presentation, such as epigenetic drugs.
8.2 Outcomes Part 2: Exploring new targets for T cells
- Sequential use of new in silico as well as laboratory tools enable selec- 
 tion of potentially safe and effective target antigens, epitopes and TCRs 
- PCT2 represents a highly and homogeneously expressed target antigen  
 for adoptive T cell therapy in TNBC with little predicted risk for on-target  
 toxicity 




Figure 1. Charting T cell evasion in BC subtypes. Luminal-A, Luminal-B and HER2 BC were studied 
using multi-parameter omics analysis and TNBC were studied using omics tools and multiplexed imaging 
techniques, resulting in subdivision into 3 spatial immunophenotypes (TNBC-excluded, TNBC-ignored 
and TNBC-inflamed). Top panel shows most prominent differences in immune contextures per BC sub-
type; arrows in second panel show the relative frequency of cancer germline antigens (CGA) and neo-
antigens (neo); arrows in third panel indicate a relative increase or decrease of different paths of T cell 
evasion; lowest panel lists possible combinations to sensitize tumors for immune therapies. * immune 
contexture of Luminal-A, Luminal-B and HER2 BC was studied based on transcriptome data only.
Is BC amenable for adoptive T cell therapy?
To date, only a hand full of studies were aimed to treat BC with adoptive T cell ther-
apy. These studies mainly used CAR-T cells that target overexpressed antigens, 
such as HER2, mucin1 (MUC1), mesothelin and more recently the receptor tyro-
sine kinase-like orphan receptor 1 (ROR1). Notwithstanding promising preclinical 
results398,435–437, the above treatments in humans were challenged by low objective 
response rates and treatment-related toxicities438. A disadvantage of CAR-T cells 
may be the limited pool of target antigens that are expressed on the tumor’s cell sur-
face, which compromises the selection of truly tumor-selective targets. In contrast, 
TCR-T cells are able to recognize extracellular as well as intracellular targets upon 
presentation via MHC-I or II, which maximizes the selection of target antigens. In this 
regard, CGAs, oncoviral or other tumor-selective intracellular targets may represent 
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interesting target candidates for TCR-T cell therapy. CGAs for example, are general-
ly present in nucleus or intracellularly, some of which having potential roles in onco-
genesis, and the thus far tested CGAs have shown clinical efficacy. In some cases, 
where CGAs were targeted with affinity-enhanced TCRs, overt toxicities were noted, 
whereas in other cases, where CGAs were targeted with natural TCRs against for 
example NY-ESO1, no toxicities were observed (see Chapter 5 for details). This 
class of antigens is predominantly expressed in immune privileged tissues of the 
germline and often highly expressed in various malignancies. Interestingly, we ob-
served that CGAs are frequently expressed in BC, particularly in TNBC (Chapter 2 
and Chapter 3), which potentially provides novel treatment options for this hard to 
treat BC subtype. Besides CGAs and other tumor-selective intracellular targets, the 
vast majority of TNBC also express at least 1 neoantigen439 (i.e.,  non-self-antigens 
that are derived from nonsynonymous mutations), which can be recognized by T 
cells440. Nevertheless, neoantigens are rarely shared among patients and require 
personalized identification and selection of tumor-reactive TCRs. CGAs and onco-
viral targets, however, are shared by a variety of patients and targeting this class of 
antigens enables stringent selection and testing of TCRs prior to patient inclusion, 
which in turn can be used as an “off-the shelf” cellular therapy.
Safety first!
In most cases, targets for TCRs are selected based on high expression in a given 
malignancy, whereas (limited) expression in healthy tissues is either accepted or 
neglected. T cells, however, are able to potently kill target antigens that express 
even very minute quantities of antigen441, which, when targeting a self-antigen, have 
resulted in several clinical examples of severe on-target toxicities (a TCR’s cog-
nate target that is expressed and recognized outside the tumor). In example, CAR-T 
cells targeting the overexpressed antigens CAIX and HER2 or TCR-T cells targeting 
MART1, gp100 or CEA have all resulted in severe on-target toxicities, which in some 
cases even resulted in fatalities (reviewed in 14,31,190). To mitigate risks for on-target 
toxicities, we utilized a stringent selection process in Chapter 6 which starts from 
absent expression of potential target antigens in healthy tissues (Figure 2). In case 
of intracellular targets, and using large public databases, we observed that PCT2 
shows tumor-restricted expression, which many intracellular targets did not, arguing 
that TCR-targets should not be blindly chosen. Furthermore, we validated absent 
expression of PCT2 in healthy tissues using qPCR and immune stainings. In fact, we 
showed that PCT2 was expressed by 85% of TNBC patients and showed homoge-
neous expression in the majority of cases. The latter finding may potentially prevent 




of antigen-negative clones). Our data so far suggest that PCT2 represents a safe 
and effective target antigen for AT in TNBC, which provided sufficient basis to contin-
ue our efforts to develop a PCT2-specific TCR.
Another safety concern of TCR engineering is off-target toxicity (a TCR’s target that 
is highly similar yet not identical to cognate target, and expressed and recognized 
outside tumor). In order to mitigate the risk for off-target toxicity, we only consider 
protein-derived epitopes that were <80% identical with any other sequence in the hu-
man proteome. Furthermore, TCRs should not be affinity-enhanced and should be 
vigorously tested according to in vitro safety experiments as proposed in ref287. Such 
experiments have been performed for the PCT2 TCR as described in Chapter 6. 
Figure 2. Risk reduction for AT-related toxicity through sequential in silico and in vitro assessment 
of antigens, epitopes and TCRs. Funnels illustrate filtering of target antigens (left), epitopes (middle) 
and TCRs (right) and include individual selection steps that are described in detail in Chapter 6. 
In Chapter 7 we have discussed recent developments regarding TCR editing tech-
nologies that potentially further minimize the risk for off-target toxicities. These de-
velopments include non-viral gene editing tools, such as CRISPR/CAS9, that enable 
insertion of TCR transgenes under the endogenous promoter while simultaneously 
knocking out the endogenous TCR loci416. Such TCR-edited cells have been shown 
to provide physiological regulation of TCR expression and at the same time prevent 
mispairing between exogenous TCR chains and endogenous TCR chains312,416. A 
recent study has shown that CRISPR-edited NY-ESO1 TCR T cells with simultane-
ous knock-out of endogenous TCR-α, TCR-β as well as PDCD1 genes were safely 
administered to 3 refractory cancer patients and resulted in long-term T cell engraft-
ment, indicating that gene-editing is feasible in a clinical setting442. Clinical response 
has not been observed yet in this study, indicating that there are still challenges to 
address. Furthermore, the latter study used a viral delivery system, which, although 
1 10 
Nucleotide 
1. Breast tumor biopsy 2. RNA-sequencing 3. Immunophenotyping 
assess spatial 
immunophenotype 
assess HLA (in silico) 
assess expression of 
TCR target antigen  












Antigen: select for absent 














1. healthy tissue 
    databases  
2. qPCR libraries 
3. healthy tissue 








1. alanine scan 
2. peptide             
     libraries 
3. TCR gene         
     editing 
Epitopes: select for non- 
































generally being more efficient, is considered less safe and has a higher regulatory 
burden for in-patient testing compared to non-viral delivery. Likely, some further op-
timizations are needed to efficiently produce edited T cells using non-viral editing 
techniques on a large scale under ATMP conditions. Taken together, this approach 
seems promising because it further improves safety of the T cell product and enables 
additional editing that potentially can enhance T cell fitness inside solid tumors.
Efficacy second!
Efficacy of AT does not only depend on the pharmacokinetics of the interaction be-
tween epitope and TCR, but also on the tumor micro-environment. Lack of efficacy 
of AT in solid tumors has been largely attributed to compromised T cell trafficking 
towards the tumor, reduced T cell persistence and reduced T cell activity due to 
the immune-suppressive microenvironment31,225,443. Similar to ICI in TNBC, AT is ex-
pected to require sensitization of tumors prior to infusion of T cells. To date, several 
trials investigate combinations of AT with chemotherapy, radiation, supplementation 
of cytokines or combination with ICI, but trials have not yet investigated combination 
treatments that are rationally selected based on their ability to counteract specific T 
cell evasive mechanisms. In particular, TNBC with an excluded or ignored immuno-
phenotype may require combinations (as proposed in Figure 1) that facilitate infiltra-
tion of adoptively transferred T cells. TNBC tumors with an inflamed phenotype are 
likely to allow infiltration of T cells but once inside the tumor, adoptively transferred T 
cells may become functionally inhibited by M2 macrophages, which could represent 
a target of choice to sensitize inflamed tumors for AT.
 
8.3 Future perspective: the next steps towards effective immune 
therapies for breast cancer
Outstanding work
Part 1: It remains elusive whether spatial immunophenotypes can evolve and change 
over time due to immune-editing or upon selected treatments. In line, it is of interest 
whether different metastatic lesions can show different spatial phenotypes, as has 
been observed in ovarian cancer444,445, which would challenge patient stratification 
and selection of optimal treatments based on spatial phenotype of a single biop-
sy. Finally, the above described evasive mechanisms, though generally recognized, 
should be functionally validated and phenotype-specific combinations with immune 




Part2: In order to develop an optimal form of AT, more TCRs need be obtained and 
tested for their efficacy and safety using pre-clinical models. With respect to com-
binatorial approaches it is of interest whether the in Part 1 identified prognostic and 
predictive markers also apply for AT and whether spatial immunophenotypes turn 
out to be stable or evolve into another phenotype upon adoptive transfer of TCR-T 
cells. In case spatial phenotypes are stable, in particular excluded and ignored phe-
notypes likely require combinatorial approaches that enable effective T cell influx of 
TCR engineered cells.
Based on the outstanding work, future research should include a series of ex vivo 
and in vivo studies as illustrated in Figure 3 and briefly exemplified and described 
below. The clinical value of spatial immunophenotypes, and its relation to T cell eva-
sion and immune-editing, is inherently linked to the question whether intra-patient 
heterogeneity with respect to spatial immunophenotypes exists. To this end, it is 
recommended to study spatial phenotypes in different metastatic lesions and moni-
tor such phenotypes over time. In this regard, our spatial phenotype gene-classifier 
represents a fast and simple way to assign spatial immunophenotypes based on 
(serial-) biopsies from different lesions. CD8 immune stainings on the other hand 
yield more confident assignments, yet the latter method depends on the availability 
of whole tissue sections. Next, the proposed combinatorial approaches to counteract 
T cell evasion and to modulate spatial immunophenotypes require functional vali-
dation. To this end, short term ex-vivo studies in which tumor pieces (from a tumor 
with known spatial immunophenotype/T cell evasive mechanism) may be cultured 
together with autologous TIL or PBMC. Exposure of such a culture to the above 
proposed drugs may reveal whether the spatial architecture of the TME can be re-
modelled or not. Direct administration of immune modulators into tumor lesions via 
microinjections446, may represent another approach to study modulation of immuno-
phenotypes in patients. This approach requires sequential biopsies and assignment 
of spatial immunophenotypes pre- and post-injection.
With respect to AT, in addition to experiments performed in Chapter 6, future studies 
should include TCR-editing of cells as well as in vitro assays to ensure safety (screen 
for recognition of peptide libraries and panels of healthy cell lines) and potency of 
TCR T cells (recognition of BC cell lines, circulating tumor cells and organoids). Safe 
and effective TCRs should then further advance into murine studies in order to test 
their efficacy in a patient-derived xenograft (PDX) model. Furthermore, PDX mouse 
models will also shed light on the modulation of spatial immunophenotypes upon ad-
ministration of tumor-specific T cells. Finally, the most safe and effective TCR should 
be tested in combination with the most effective immune modulator (which may be 




Once optimal TCRs and drugs have been selected and validated, different immuno-
phenotype-specific combinatorial approaches should advance into clinical trials. In 
the clinical setting (exemplified in Figure 4), a patients’ biopsy can be transcriptome 
profiled in order to assign the spatial immunophenotype using the gene-classifier, 
the HLA-status with in silico typing algotithms (see also Chapter 5) and to assess 
expression of TCR target antigens. In case the patient expresses HLA-A2 as well as 
the target antigen, she could advance to AT combined with immunophenotype-spe-
cific modulators. In case the patient is not eligible for AT, she could advance to ICI in 
combination with immunophenotype-specific modulators.
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Figure 4. Patient and treatment selections into clinical practice. Flow-chart shows proposed individ-
ual steps for selection of (combination) i mune therapies to treat BC.
Figure 3. Future studies to select immune modulators and TCRs. Individual boxes visualize ap-
proaches to pursue the outstanding work based on research from Part 1 (left) and Part 2 (right) of this 
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Cancer immunotherapy represents a collection of effective new treatment options 
for a number of tumor types. Nevertheless, not all tumor types respond equally well 
to current immune therapies. Zooming in on breast cancer, this type of tumor is 
currently confronted by a number of gaps in its treatment portfolio, namely: low re-
sponse rates and lack of predictive markers for immune therapies; lack of druggable 
targets that counteract T cell evasion; and lack of safe and effective target antigens 
for adoptive T cell therapies.
Chapter 1 provides a short introduction to the thesis’ research which includes a 
brief overview of standard treatment as well as immunotherapeutic approaches and 
their current challenges in breast cancer. According to these challenges, this thesis 
followed 2 main research lines:
-Charting T cell evasion: In Part 1 of this thesis (Chapter2-4) we focused on 
the knowledge gap regarding T cell evasive mechanisms, which, provides a 
basis for patient stratification and selection of combination therapies.
-Exploring new targets for T cells: In Part 2 of this thesis (Chapter 5-7) we 
focused on the identification and selection of safe and effective target anti-
gens and corresponding TCRs for adoptive T cell therapy for TNBC (one of 
the subtypes of breast cancer).
In Chapter 2 we reviewed recent literature regarding the composition of TILs, their 
prognostic and predictive value, and the antigenicity of breast cancer subtypes (Lu-
minal-A, Luminal-B, HER2 and TNBC), which suggest that BC subtypes are not 
equally immunogenic and do not equally respond to immune therapies. Further-
more, we provided an overview of recent immune therapy trials in BC and propose a 
strategy to select ER+ and ER- patients for (combination-) immune therapies.
In Chapter 3 we studied large cohorts of breast cancer subtypes for the differen-
tial prognostic value of various immune parameter and the occurrence of immune 
evasive strategies in silico. Our data suggest that not merely CD8 T cell presence 
itself, but rather clonality, subset distribution, and co-inhibition of T cells as well as 
antigen presentation reflect the occurrence of a CD8 T cell response in BC subtypes. 
According to our data, such CD8 T cell responses have been aborted by distinct T 
cell suppressive mechanisms, such as alteration in metabolic pathways, decreased 
expression of T cell adhesion molecules, enhanced expression of immunosuppres-




our data indicates that next to TNBC also HER2 and a subset of luminal B patients 
may benefit from immune therapies with subtype-specific combinations.
In Chapter 4 we zoomed in on TNBC and studied the prognostic and predictive 
value of spatial immune contextures in untreated and anti-PD1 treated TNBC. We 
identified 3 immunophenotypes based on the spatial localization of CD8 T cells: 
excluded (T cells restricted to the invasive margin), ignored (no T cells present) 
and inflamed (T cells present in tumor center). We were able to capture these im-
munophenotypes by a gene classifier that predicts survival in untreated TNBC and 
various other cancers as well as anti-PD1 response of metastatic TNBC and mela-
noma. Importantly, our in-depth analyses revealed distinct T cell evasive pathways 
that advocate spatial immunophenotype-specific combinations, such as blockade 
of TGFb- or VEGF-pathways in case of the excluded phenotype, or blockade of M2 
macrophages or WNT-pathway in case of the ignored phenotype to boost the effica-
cy of ICI in TNBC.
in Chapter 5, we reviewed in silico as well as laboratory tools and strategies to select 
target antigens, epitopes and TCRs for adoptive T cell therapy as well as tools that 
enable charting of T cell evasive mechanisms which can be used to select combina-
tion therapies.
In Chapter 6, we applied these technologies to large proprietary and public databas-
es covering transcriptome data from tumor and healthy tissues and identified PCT2, 
as a TNBC-selective inracellular target antigen. We verified absent expression in 
healthy tissue and high- and homogenous expression in TNBC using qPCR and im-
mune stainings. Furthermore, we selected unique and immunogenic target epitopes 
using a series of in silico predictions, HLA-peptidome analysis and in vitro binding 
assays. Finally, we identified a PCT2-specific TCR which can be further exploited for 
the development of adoptive T cell therapy for TNBC.
In Chapter 7 we listed and described recent developments with respect to TCR-edit-
ing technologies that enable insertion of TCR transgenes into the endogenous TCR 
loci thereby facilitating endogenous regulation of TCR transgenes. Furthermore, 
these technologies enable simultaneous knock out of endogenous TCRα and TCRβ 
which reduces mispairing of TCR chains, which in turn limits toxicity risks of TCR 
engineered cells.
In Chapter 8, the main findings of Parts 1 and 2 were discussed in a broader con-
text. Outstanding questions were formulated, and according to these questions, fu-





Immunotherapie is een effectieve nieuwe behandelingsoptie voor kanker. In de regel 
houdt deze therapie in dat je tumorcellen niet direct behandeld, maar indirect door 
de immuun cellen van de patiënt te activeren, waardoor deze cellen, met name T 
cellen, de tumor aanvallen. Echter, niet alle tumortypen reageren even goed op deze 
therapieën. Zo reageert bij borstkanker slechts een relatief kleine fractie van de 
patiënten op immunotherapie, en dit varieert sterk afhankelijk van het borstkanker 
subtype. Het gebrek aan kennis hoe we het beste immunotherapie in borstkanker 
kunnen ondersteunen, dwz onderzoek naar de onderliggende reden waarom T cel-
len hun taak niet uitvoeren, en hoe we dit kunnen verbeteren, is het onderwerp van 
dit proefschrift.
Hoofdstuk 1 leidt het onderzoek in, en geeft een kort overzicht van zowel stan-
daardbehandelingen als immunotherapiën bij borstkanker. Ondanks vooruitgang in 
klinische effecten door immunotherapie, is er duidelijk ruimte voor verbetering. Hier-
toe is in dit proefschrift onderzoek gedaan volgens 2 hoofdlijnen:
-In kaart brengen van redenen waarom T cellen hun taak niet uitvoeren: 
In deel 1 van dit proefschrift (hoofdstuk 2-4) hebben we ons gericht op mech-
anismen van borstkanker die T cellen om de tuin leiden, en welke een ba-
sis kunnen bieden voor de ontwikkeling van factoren welke voorspellen of 
een patiënt wel/niet gaat reageren, en hoe het beste combinatietherapieën 
te kiezen.
-Verkenning van nieuwe targets voor T-cellen: In deel 2 van dit proefschrift 
(hoofdstuk 5-7) hebben we ons gericht op de identificatie en selectie van veil-
ige en effectieve doelwit-antigenen en bijbehorende T cel receptoren (TCRs; 
receptoren waarmee T cellen antigenen op tumorcellen herkennen) voor 
adoptieve T-celtherapie bij TNBC.
In Hoofdstuk 2 hebben we recente literatuur samengevat en besproken met betrek-
king tot de samenstelling van tumor-infiltrerende immuuncellen, hun voorspellende 
waarde wat betreft patiënt overleving, en immunogeniciteit van borstkanker sub-
typen. Verder hebben we een overzicht gegeven van recente klinische studies die 
gericht zijn op immunotherapie in borstkanker, en een strategie voorgesteld om zo-
genaamde oestrogeen receptor-positieve en negatieve patiënten te selecteren voor 
(combinatie-) immunotherapieën.




subtypen bestudeerd wat betreft verschillende immuun parameters en het optreden 
van T cel ontwijkende mechanismen. Onze gegevens suggereren dat niet alleen de 
aanwezigheid van CD8 T-cellen, maar eerder functionele karakteristieken  bepal-
end zijn voor het optreden van een effectieve anti-tumor T-cel respons. Interessant 
is dat in de verschillende subtypen, functionele T cel responsen op verschillende 
wijzen ontweken lijken te worden. Bovendien geven onze gegevens aan dat naast 
het TNBC subtype ook HER2 en een subset van luminale B-patiënten baat kunnen 
hebben bij immunotherapieën die ondersteund worden met subtype-specifieke be-
handeling.
In Hoofdstuk 4 hebben we TNBC uitgelicht, en hebben we de ruimtelijke verdeling 
van immuun cellen in onbehandelde en anti-PD1 behandelde patiënten bestudeerd. 
We identificeerden 3 fenotypen op basis van de ruimtelijke lokalisatie van CD8 T-cel-
len. Naast immuun kleuringen konden we deze fenotypen vaststellen met een serie 
genen (een zogenaamde classifier) die de overleving in TNBC voorspelt, evenals de 
anti-PD1-respons van uitgezaaid TNBC. Belangrijk is dat onze diepgaande analyses 
verschillende T-cel ontwijkende routes aan het licht brachten welke pleiten voor het 
belang van ruimtelijke informatie wat betreft CD8 T cellen om juiste behandel keuzes 
te maken voor TNBC.
In Hoofdstuk 5 hebben we computer en laboratoriumtechnieken besproken om 
doelwit-antigenen, epitopen en TCRs te selecteren voor adoptieve T-celtherapie, 
evenals up-to-date technieken om T-cel ontwijking in kaart te brengen. Slimme keuz-
es van dergelijke technieken maakt het mogelijk op rationele wijze combinatiether-
apieën te selecteren.
In Hoofdstuk 6 hebben we deze technologieën toegepast op grote databases die 
transcriptoom data van tumor en gezonde weefsels bevatten en op deze wijze PCT2 
geïdentificeerd als een TNBC-selectief doelwit-antigeen. We verifieerden afwezige 
expressie van dit antigeen in gezond weefsel en toonden hoge en homogene ex-
pressie in TNBC. Verder selecteerden we unieke en immunogene epitopen, en tot 
slot hebben we een PCT2 specifieke TCR geïdentificeerd die verder kan worden 
getest voor de ontwikkeling van adoptieve T-celtherapie.
In Hoofdstuk 7 hebben we recente technische noviteit besproken die endogene 
regulering toelaat van TCR-transgenen, zogenaamde TCR-gene editing. Deze tech-
nologie zorgt verder voor uit-knocking van endogene TCR genen waardoor risico’s 
van toxiciteit sterk vermindert.
In Hoofdstuk 8 werden de belangrijkste bevindingen van deel 1 en 2 bediscussieert. 
Openstaande onderzoeksvragen zijn geformuleerd, en aan de hand van deze vra-
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